Crystalline forms of phosphoinositide 3-kinase (PI3K) inhibitors
Patent Information
- Application Number
- JP2021512576
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-10-17
- Filing Date
- 2019-09-04
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2039-09-04
Smart Images

Figure 0007592006000044 
Figure 0007592006000045 
Figure 0007592006000046
Abstract
Description
[Technical field]
[0001] The present invention relates to salts and crystalline forms of the PI3K inhibitors 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide and 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, which are useful in the treatment of cancer and other diseases. Background of the Invention
[0002] The compounds 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide having formula A, 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide having formula B and 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide having formula C. [ka] is a phosphoinositide 3-kinase (PI3K) inhibitor useful for the treatment of various diseases, including cancer. For drug development, it is generally advantageous to utilize a form of the drug that has desirable properties with respect to preparation, purification, reproducibility, stability, bioavailability, and other characteristics. Thus, the salt and crystalline forms of the compounds of Formula A, Formula B, and Formula C presented herein address the continuing need for the development of PI3K inhibitors for the treatment of serious diseases. Summary of the Invention
[0003] The present invention relates to salts and crystalline forms of a compound of formula A, crystalline forms of a compound of formula B and crystalline forms of a compound of formula C: [ka] to provide.
[0004] The present invention further provides compositions comprising the salts and crystalline forms of the compound of formula A as set forth herein and at least one pharma- ceutically acceptable carrier. The present invention further provides compositions comprising the crystalline form of the compound of formula B and at least one pharma- ceutically acceptable carrier. The present invention further provides compositions comprising the crystalline form of the compound of formula C and at least one pharma- ceutically acceptable carrier.
[0005] The present invention further provides processes for preparing the salts and crystalline forms of the present invention.
[0006] The invention further provides a method of treating a disease associated with aberrant expression or activity of PI3K kinase in a patient, comprising administering to the patient a therapeutically effective amount of a salt or crystalline form of the invention. [Brief description of the drawings]
[0007] [Figure 1]FIG. 1 shows the XRPD pattern for 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IA. [Diagram 2] 1 shows the results of a DSC experiment for 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IA. [Diagram 3] 1 shows the results of a TGA experiment for 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IA. [Figure 4] FIG. 2 shows the XRPD pattern for 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IIA. [Diagram 5] FIG. 1 shows the results of a DSC experiment for 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IIA. [Figure 6] 1 shows the results of a TGA experiment for 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IIA. [Figure 7] FIG. 1 shows the XRPD pattern for 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IIIA. [Figure 8]1 shows the results of a DSC experiment for 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IIIA. [Figure 9] 1 shows the results of a TGA experiment for 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IIIA. [Figure 10] 1 shows the XRPD pattern for 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, crystal form IB. [Figure 11] 1 shows the results of a DSC experiment for 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, crystal form IB. [Figure 12] FIG. 1 shows the XRPD pattern for 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, crystalline form IIB. [Figure 13] FIG. 1 shows the results of a DSC experiment for 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, crystalline form IIB. [Figure 14] 1 shows the XRPD pattern for 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, crystalline form IC. [Figure 15] FIG. 1 shows the results of a DSC experiment on 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, crystal form IC. [Figure 16A] Thermal ellipsoids drawn at a probability level of 30% are used to depict the asymmetric crystalline unit of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide, methanol solvate form. [Figure 16B] A thermal ellipsoid drawn at a probability level of 30% is used to represent the crystalline unit of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] The present invention relates inter alia to salts and crystalline forms of the PI3K inhibitor 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide having formula A: [ka] This is useful, for example, in preparing solid dosage forms of the compounds for the treatment of various diseases, including cancer.
[0009] The present invention also relates, inter alia, to a crystalline form of the PI3K inhibitor 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, having formula B: [ka]
[0010] The present invention also relates, inter alia, to a crystalline form of the PI3K inhibitor 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, having formula C: [ka]
[0011] Generally, different crystalline forms of the same substance have different bulk properties, e.g., with respect to hygroscopicity, solubility, stability, etc. Forms with high melting points often have good thermodynamic stability, which is advantageous for increasing the shelf life of drug formulations containing solids. Forms with low melting points are often less thermodynamically stable, but they are advantageous in that they lead to higher water solubility and higher bioavailability of the drug. Forms with low hygroscopicity are desirable for their stability to heat and humidity, and resist degradation during long-term storage. Anhydrous forms are often desirable because they can be consistently produced without concern for changes in weight or composition due to changes in solvent or water content. On the other hand, hydrated or solvated forms may be advantageous in that they are less likely to be hygroscopic and may also show improved stability to humidity under storage conditions.
[0012] As used herein, the term "crystalline form" is meant to refer to a particular lattice configuration of a crystalline substance. Different crystalline forms of the same substance generally have different crystal lattices (e.g., unit cells), which are due to different physical properties specific to each crystalline form. In some cases, different lattice configurations have different water or solvent contents. Different crystalline lattices can be identified by solid-state characterization methods, for example, by X-ray powder diffraction (XRPD). Other characterization methods, such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption (DVS), solid-state NMR, etc., further aid in the identification of crystalline forms, as well as the determination of stability and solvent / water content.
[0013] Crystalline forms of a substance include both solvated (e.g., hydrated) and unsolvated (e.g., anhydrous) forms. Hydrated forms are crystalline forms that contain water in the crystal lattice. Hydrated forms may be stoichiometric hydrates, where water is present in the lattice at a particular water / molecule ratio, such as hemihydrate, monohydrate, dihydrate, etc. Hydrated forms may also be non-stoichiometric, where the water content is variable and dependent on external conditions such as humidity.
[0014] Crystalline forms are most commonly characterized by XRPD. An XRPD pattern of reflections (peaks) is typically considered a fingerprint of a particular crystal form. It is well known that the relative intensities of XRPD peaks can vary widely depending on, among other things, sample preparation techniques, crystal size distribution, filters, sample mounting procedures, and the particular instrument used. In some cases, new peaks can be observed or existing peaks can disappear depending on the type of instrument or settings (e.g., whether a Ni filter is used). As used herein, the term "peak" refers to a reflection having a relative height / intensity of at least about 4% of the maximum peak height / intensity. Furthermore, instrumental variations and other factors can affect 2-theta values. Thus, peak assignments such as those reported herein can vary by plus or minus about 0.2° (2-theta), and the term "substantially" as used herein in the context of XRPD is meant to encompass the variations described above.
[0015] Similarly, temperature measurements for DSC, TGA, or other thermal experiments may vary by about ±4° C. depending on the instrument, the particular settings, sample preparation, etc. For example, for DSC, it is known that the observed temperatures depend on the rate of temperature change as well as the sample preparation technique and particular instrument utilized. Thus, values reported herein for DSC thermograms, as noted above, may vary by ±4° C. Thus, it is understood that crystalline forms reported herein having DSC thermograms "substantially" as shown in any of the figures accommodate such variations.
[0016] Crystalline forms of the compound of formula A The compound of formula A may be isolated in multiple crystalline forms, including, for example, crystalline forms that are anhydrous and / or unsolvated or solvated. In some embodiments, the crystalline form of the compound of formula A is solvated. In some embodiments, the crystalline form of the compound of formula A is anhydrous. In some embodiments, the crystalline form of the compound of formula A is unsolvated. In some embodiments, the crystalline form of the compound of formula A is anhydrous and unsolvated. By "anhydrous" is meant that the crystalline form of the compound of formula A is essentially free of bound water in the crystal lattice structure, i.e., the compound does not form crystalline hydrates.
[0017] In some embodiments, the present application provides a process for preparing a crystalline form of the compound 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide. In some embodiments, the process includes dissolving 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide in a solvent to form a mixture and crystallizing the compound from the mixture.
[0018] In some embodiments, the solvent comprises isopropyl acetate. In some embodiments, the solvent further comprises heptane.
[0019] In some embodiments, the solvent comprises methanol.
[0020] In some embodiments, the process further comprises heating the mixture to a temperature of about 70°C to about 90°C.
[0021] In some embodiments, the process further comprises heating the mixture to a temperature of about 50°C to about 70°C.
[0022] In some embodiments, the process further comprises cooling the mixture to room temperature.
[0023] The present application further provides a crystalline form of the compound 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide prepared according to the processes set forth herein. In some embodiments, the crystalline form is Form IA as described herein. In some embodiments, the crystalline form is Form IIA as described herein. In some embodiments, the crystalline form is Form IIIA as described herein.
[0024] In some embodiments, the present application provides a process for preparing the hydrobromide salt of the compound 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide. In some embodiments, the process includes dissolving a compound of formula A in a solvent to form a mixture and adding hydrobromic acid to the mixture.
[0025] In some embodiments of the process for preparing the hydrobromide salt, the solvent comprises methanol.
[0026] In some embodiments of the process for preparing the hydrobromide salt, hydrobromic acid is added to the mixture as an aqueous solution of hydrobromic acid.
[0027] In some embodiments of the process for preparing the hydrobromide salt, an excess of hydrobromic acid is added to the mixture based on one equivalent of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide.
[0028] In some embodiments of the process for preparing the hydrobromide salt, about 1.1 to about 1.5 equivalents of hydrobromic acid are added to the mixture based on 1 equivalent of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide.
[0029] In some embodiments of the process for preparing a hydrobromide salt, the process further comprises substantially isolating 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide salt.
[0030] In some embodiments of the process for preparing the hydrobromide salt, 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide is isolated as a crystalline form.
[0031] In some embodiments of the process for preparing the hydrobromide salt, 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide salt is isolated as a methanol solvate crystalline form.
[0032] In some embodiments, the application further provides the hydrobromide salt of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide prepared according to the processes set forth herein. In some embodiments, the hydrobromide salt is crystalline. In some embodiments, the hydrobromide salt is a solvated crystalline form. In some embodiments, the hydrobromide salt is a methanol solvated crystalline form.
[0033] In some embodiments, the crystalline forms of the present invention are substantially isolated. By "substantially isolated" is meant that a particular crystalline form of the compound of formula A is at least partially isolated from impurities. For example, in some embodiments, the crystalline forms of the present invention contain less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 2.5%, less than about 1%, or less than about 0.5% of impurities. Impurities generally include those that are not substantially isolated crystalline forms, including, for example, other crystalline forms and other substances.
[0034] In some embodiments, the crystalline form of the compound of formula A is substantially free of other crystalline forms. The phrase "substantially free of other crystalline forms" means that a particular crystalline form of the compound of formula A contains greater than about 80%, greater than about 90%, greater than about 95%, greater than about 98%, greater than about 99%, or greater than about 99.5% by weight of a particular crystalline form.
[0035] Crystalline Form IA of the compound of formula A In some embodiments, the crystalline form of the compound of formula A is Form IA. In some embodiments, the crystalline form IA of the compound of formula A is anhydrous and anhydrous. The preparation of the compound of formula A in Form IA is described in Example 1. The crystalline form IA of the compound of formula A can be generally prepared as described in Example 2.
[0036] Crystalline form IA of the compound of formula A can be identified, for example, by unique signatures for X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA). In some embodiments, crystalline form IA of the compound of formula A is characterized by an XRPD pattern substantially as shown in Figure 1. The peaks of the XRPD pattern are listed in Table 1.
[0037] In some embodiments, crystalline form IA of the compound of formula A is characterized by an XRPD pattern including a peak at 8.6°±0.2° in 2θ. In some embodiments, crystalline form IA of the compound of formula A is characterized by an XRPD pattern including a peak at 9.5°±0.2° in 2θ. In some embodiments, crystalline form IA of the compound of formula A is characterized by an XRPD pattern including a peak at 10.3°±0.2° in 2θ. In some embodiments, crystalline form IA of the compound of formula A is characterized by an XRPD pattern including a peak at 14.9°±0.2° in 2θ.
[0038] In some embodiments, the crystalline form IA of the compound of formula A has an XRPD pattern comprising the following peaks at 2θ: 8.6°±0.2°; 9.5°±0.2°; 10.3°±0.2°; 13.0°±0.2°; 13.6°±0.2°; 14.2°±0.2°; and 14.9°±0.2°. In some embodiments, crystalline form IA of the compound of formula A has an XRPD pattern including the following peaks in 2θ: 8.6°±0.2°; 9.5°±0.2°; 10.3°±0.2°; 14.9°±0.2°; 17.3°±0.2°; 17.8°±0.2°; 19.0°±0.2°; 19.2°±0.2°; 20.1°±0.2°; 20.6°±0.2°; 21.2°±0.2°; 22.2°±0.2°; 24.0°±0.2°; 26.8°±0.2°; and 28.7°±0.2°. In some embodiments, the crystalline form IA of the compound of formula A has an XRPD pattern comprising the following peaks in 2θ: 10.3°±0.2°; 14.9°±0.2°; 17.3°±0.2°; 19.2°±0.2°; and 24.0°±0.2°.
[0039] In some embodiments, crystalline form IA of the compound of formula A has an XRPD pattern including two or more, three or more, or four or more of the following peaks in 2θ: 8.6°±0.2°; 9.5°±0.2°; 10.3°±0.2°; 13.0°±0.2°; 13.6°±0.2°; 14.2°±0.2°; 14.9°±0.2°; 17.3°±0.2°; 19.2°±0.2°; 20.6°±0.2°; 24.0°±0.2°; and 28.7°±0.2°. In some embodiments, crystalline form IA of the compound of formula A has an XRPD pattern comprising two or more, three or more, or four or more of the following peaks in 2θ: 8.6°±0.2°; 9.5°±0.2°; 10.3°±0.2°; 14.9°±0.2°; 17.3°±0.2°; 17.8°±0.2°; 19.0°±0.2°; 19.2°±0.2°; 20.1°±0.2°; 20.6°±0.2°; 21.2°±0.2°; 22.2°±0.2°; 24.0°±0.2°; 26.8°±0.2°; and 28.7°±0.2°. In some embodiments, crystalline form IA of the compound of formula A has an XRPD pattern including two or more, three or more, or four or more of the following peaks in 2θ: 9.5°±0.2°; 10.3°±0.2°; 14.9°±0.2°; 17.3°±0.2°; 19.2°±0.2°; 20.6°±0.2°; 24.0°±0.2°; and 28.7°±0.2°.
[0040] In some embodiments, Form IA of the compound of formula A is characterized by a DSC thermogram comprising an endothermic peak having a maximum at about 193° C. In some embodiments, crystalline Form IA of the compound of formula A has a DSC thermogram substantially as shown in FIG.
[0041] In some embodiments, the crystalline form IA of the compound of formula A has a TGA trace substantially as shown in FIG.
[0042] Crystalline Form IIA of the compound of formula A In some embodiments, the crystalline form of the compound of formula A is Form IIA. In some embodiments, the crystalline form of the compound of formula A is anhydrous and anhydrous. This crystalline form can be prepared generally as described in Example 3.
[0043] Crystalline Form IIA of the compound of Formula A can be identified, for example, by unique signatures for X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA). In some embodiments, crystalline Form IIA of the compound of Formula A is characterized by an XRPD pattern substantially as shown in Figure 4. The peaks of the XRPD pattern are listed in Table 2.
[0044] In some embodiments, crystalline form IIA of the compound of formula A is characterized by an XRPD pattern that includes a peak at 9.1°±0.2° in 2θ. In some embodiments, crystalline form IIA of the compound of formula A is characterized by an XRPD pattern that includes a peak at 11.1°±0.2° in 2θ. In some embodiments, crystalline form IIA of the compound of formula A is characterized by an XRPD pattern that includes a peak at 21.9°±0.2° in 2θ. In some embodiments, crystalline form IIA of the compound of formula A is characterized by an XRPD pattern that includes a peak at 12.6°±0.2° in 2θ. In some embodiments, crystalline form IIA of the compound of formula A is characterized by an XRPD pattern that includes a peak at 13.6°±0.2° in 2θ. In some embodiments, crystalline form IIA of the compound of formula A is characterized by an XRPD pattern that includes a peak at 18.0°±0.2° in 2θ. In some embodiments, crystalline Form IIA of the compound of formula A is characterized by an XRPD pattern comprising a peak at 19.0°±0.2° in 2θ.
[0045] In some embodiments, crystalline form IIA of the compound of formula A has an XRPD pattern comprising the following peaks in 2θ: 9.1°±0.2°; 11.1°±0.2°; 12.6°±0.2°; and 13.5°±0.2°. In some embodiments, crystalline form IIA of the compound of formula A has an XRPD pattern including the following peaks in 2θ: 9.1°±0.2°; 11.1°±0.2°; 12.6°±0.2°; 13.5°±0.2°; 16.1°±0.2°; 16.9°±0.2°; 18.0°±0.2°; 18.4°±0.2°; 19.0°±0.2°; 19.7°±0.2°; 20.1°±0.2°; 20.5°±0.2°; 21.9°±0.2°; 23.7°±0.2°; 23.8°±0.2°; 25.1°±0.2°; 25.3°±0.2°; 25.8°±0.2°; and 27.3°±0.2°. In some embodiments, crystalline form IIA of the compound of formula A has an XRPD pattern comprising the following peaks in 2θ: 12.6°±0.2°; 18.0°±0.2°; 19.0°±0.2°; and 21.9°±0.2°.
[0046] In some embodiments, crystalline form IIA of the compound of formula A has an XRPD pattern including two or more, three or more, or four or more of the following peaks in 2θ: 9.1°±0.2°; 11.1°±0.2°; 12.6°±0.2°; 13.5°±0.2°; 18.0°±0.2°; 19.0°±0.2°; 20.5°±0.2°; and 21.9°±0.2°. In some embodiments, crystalline Form IIA of the compound of Formula A has an XRPD pattern comprising two or more, three or more, or four or more of the following peaks in 2θ: 9.1°±0.2°; 11.1°±0.2°; 12.6°±0.2°; 13.5°±0.2°; 16.1°±0.2°; 16.9°±0.2°; 18.0°±0.2°; 18.4°±0.2°; 19.0°±0.2°; 19.7°±0.2°; 20.1°±0.2°; 20.5°±0.2°; 21.9°±0.2°; 23.7°±0.2°; 23.8°±0.2°; 25.1°±0.2°; 25.3°±0.2°; 25.8°±0.2°; and 27.3°±0.2°. In some embodiments, crystalline Form IIA of the compound of formula A has an XRPD pattern comprising two or more, three or more, or four or more of the following peaks in 2θ: 12.6°±0.2°; 18.0°±0.2°; 19.0°±0.2°; 20.5°±0.2°; and 21.9°±0.2°.
[0047] In some embodiments, Form IIA of the compound of formula A is characterized by a DSC thermogram comprising an endothermic peak having a maximum at about 180° C. In some embodiments, crystalline Form IIA of the compound of formula A has a DSC thermogram substantially as shown in FIG.
[0048] In some embodiments, the crystalline form IIA of the compound of formula A has a TGA trace substantially as shown in FIG.
[0049] Crystalline Form IIIA of the compound of formula A In some embodiments, the crystalline form of the compound of formula A is Form IIIA. In some embodiments, the crystalline form IIIA of the compound of formula A is anhydrous and ansolvated. This crystalline form can be prepared generally as described in Example 4.
[0050] Crystalline Form IIIA of the compound of formula A can be identified, for example, by unique signatures for X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA). In some embodiments, crystalline Form IIIA of the compound of formula A is characterized by an XRPD pattern substantially as shown in Figure 7. The peaks of the XRPD pattern are listed in Table 3.
[0051] In some embodiments, crystalline form IIIA of the compound of formula A is characterized by an XRPD pattern that includes a peak at 8.1°±0.2° in 2θ. In some embodiments, crystalline form IIIA of the compound of formula A is characterized by an XRPD pattern that includes a peak at 10.6°±0.2° in 2θ. In some embodiments, crystalline form IIIA of the compound of formula A is characterized by an XRPD pattern that includes a peak at 13.5°±0.2° in 2θ. In some embodiments, crystalline form IIIA of the compound of formula A is characterized by an XRPD pattern that includes a peak at 14.2°±0.2° in 2θ. In some embodiments, crystalline form IIIA of the compound of formula A is characterized by an XRPD pattern that includes a peak at 20.3°±0.2° in 2θ.
[0052] In some embodiments, the crystalline form IIIA of the compound of formula A has an XRPD pattern comprising the following peaks in 2θ: 8.1°±0.2°; 10.6°±0.2°; 13.5°±0.2°; and 14.2°±0.2°. In some embodiments, the crystalline form IIIA of the compound of formula A has an XRPD pattern comprising the following peaks in 2θ: 10.6°±0.2°; 13.5°±0.2°; 14.2°±0.2°; 16.4°±0.2°; 17.1°±0.2°; 17.9°±0.2°; 20.3°±0.2°; 20.8°±0.2°; 24.1°±0.2°; 24.6°±0.2°; 24.8°±0.2°; and 27.5°±0.2°. In some embodiments, crystalline form IIIA of the compound of formula A has an XRPD pattern comprising the following peaks in 2θ: 10.6°±0.2°; 13.5°±0.2°; 14.2°±0.2°; and 20.3°±0.2°.
[0053] In some embodiments, crystalline form IIIA of the compound of formula A has an XRPD pattern including two or more, three or more, or four or more of the following peaks in 2θ: 8.1°±0.2°; 10.6°±0.2°; 13.5°±0.2°; 14.2°±0.2°; 16.4°±0.2°; 17.1°±0.2°; 17.9°±0.2°; 20.3°±0.2°; and 24.1°±0.2°. In some embodiments, crystalline form IIIA of the compound of formula A has an XRPD pattern including two or more, three or more, or four or more of the following peaks in 2θ: 10.6°±0.2°; 13.5°±0.2°; 14.2°±0.2°; 16.4°±0.2°; 17.1°±0.2°; 17.9°±0.2°; 20.3°±0.2°; 20.8°±0.2°; 24.1°±0.2°; 24.6°±0.2°; 24.8°±0.2°; and 27.5°±0.2°. In some embodiments, crystalline form IIIA of the compound of formula A has an XRPD pattern including two or more, three or more, or four or more of the following peaks in 2θ: 10.6°±0.2°; 13.5°±0.2°; 14.2°±0.2°; 16.4°±0.2°; 17.1°±0.2°; 17.9°±0.2°; 20.3°±0.2°; and 24.1°±0.2°.
[0054] In some embodiments, Form IIIA of the compound of formula A is characterized by a DSC thermogram comprising an endothermic peak having a maximum at about 143° C. In some embodiments, crystalline Form IIIA of the compound of formula A has a DSC thermogram substantially as shown in FIG.
[0055] In some embodiments, the crystalline form IIIA of the compound of formula A has a TGA trace substantially as shown in FIG.
[0056] Hydrobromide of formula A In some embodiments, the present application provides a hydrobromide salt of a compound of formula A. In some embodiments, the hydrobromide salt of a compound of formula A is 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide in a 1:1 stoichiometric ratio to hydrobromic acid. The hydrobromide salt form can be prepared generally as described in Example 11.
[0057] In some embodiments, the hydrobromide salt of the compound of formula A is crystalline. In some embodiments, the hydrobromide salt of the compound of formula A is in a solvated crystal form. In some embodiments, the hydrobromide salt of the compound of formula A is in a methanol solvate crystal form.
[0058] Crystalline forms of the compound of formula B The compound of formula B may be isolated in multiple crystalline forms, including, for example, crystalline forms that are anhydrous and / or nonsolvated. In some embodiments, the crystalline form of the compound of formula B is anhydrous. In some embodiments, the crystalline form of the compound of formula B is nonsolvated. In some embodiments, the crystalline form of the compound of formula B is anhydrous and nonsolvated. By "anhydrous" is meant that the crystalline form of the compound of formula B is essentially free of bound water in the crystal lattice structure, i.e., the compound does not form crystalline hydrates.
[0059] In some embodiments, the crystalline forms provided herein can be prepared, for example, by a process that includes dissolving 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide in a solvent to form a mixture and crystallizing the compound from the mixture.
[0060] In some embodiments, the process further comprises heating the mixture to a temperature of about 70° C. to about 90° C. In some embodiments, the process further comprises cooling the mixture to room temperature.
[0061] In some embodiments, the solvent comprises isopropyl acetate. In some embodiments, the solvent further comprises heptane.
[0062] In some embodiments, the present application provides a crystalline form of the compound 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide prepared according to the processes set forth herein. In some embodiments, the crystalline form is Form IB as described herein. In some embodiments, the crystalline form is Form IIB as described herein.
[0063] In some embodiments, the crystalline form of the present invention is substantially isolated. By "substantially isolated" is meant that the particular crystalline form of the compound of formula B is at least partially isolated from impurities. For example, in some embodiments, the crystalline form of the present invention contains less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 2.5%, less than about 1%, or less than about 0.5% of impurities. Impurities generally include those that are not substantially isolated crystalline forms, including, for example, other crystalline forms and other substances.
[0064] In some embodiments, the crystalline form of the compound of formula B is substantially free of other crystalline forms. The phrase "substantially free of other crystalline forms" means that a particular crystalline form of the compound of formula B contains greater than about 80%, greater than about 90%, greater than about 95%, greater than about 98%, greater than about 99%, or greater than about 99.5% by weight of a particular crystalline form.
[0065] Crystal form IB of the compound of formula B In some embodiments, the crystalline form of the compound of formula B is Form IB. In some embodiments, the crystalline form IB of the compound of formula B is anhydrous and anhydrous. The preparation of the compound of formula B is described in Examples 5 and 6. The crystalline form IB can be generally prepared as described in Example 7.
[0066] Crystalline form IB of the compound of formula B can be identified, for example, by a unique signature for X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC). In some embodiments, crystalline form IB of the compound of formula B is characterized by an XRPD pattern substantially as shown in Figure 10. The peaks of the XRPD pattern are listed in Table 4.
[0067] In some embodiments, crystalline form IB of the compound of formula B is characterized by an XRPD pattern that includes a peak at 6.2°±0.2° in 2θ. In some embodiments, crystalline form IB of the compound of formula B is characterized by an XRPD pattern that includes a peak at 15.6°±0.2° in 2θ. In some embodiments, crystalline form IB of the compound of formula B is characterized by an XRPD pattern that includes a peak at 20.7°±0.2° in 2θ. In some embodiments, crystalline form IB of the compound of formula B has an XRPD pattern that includes the following peaks in 2θ: 6.2°±0.2°; 15.6°±0.2°; 16.7°±0.2°; 20.7°±0.2°; and 23.2°±0.2°. In some embodiments, crystalline form IB of the compound of formula B has an XRPD pattern including the following peaks in 2θ: 6.2°±0.2°; 10.4°±0.2°; 11.4°±0.2°; 11.6°±0.2°; 12.0°±0.2°; 13.9°±0.2°; 14.4°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; 20.7°±0.2°; and 23.2°±0.2°. In some embodiments, crystalline form IB of the compound of formula B has an XRPD pattern that includes the following peaks in 2θ: 6.2°±0.2°; 12.0°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; 19.3°±0.2°; 20.7°±0.2°; 23.2°±0.2°; and 27.1°±0.2°. In some embodiments, crystalline form IB of the compound of formula B has an XRPD pattern that includes the following peaks in 2θ: 6.2°±0.2°; 10.4°±0.2°; 11.4°±0.2°; 11.6°±0.2°; 12.0°±0.2°; 13.9°±0.2°; and 14.4°±0.2°.
[0068] In some embodiments, crystalline form IB of the compound of formula B has an XRPD pattern that includes two or more, three or more, or four or more of the following peaks in 2θ: 6.2°±0.2°; 10.4°±0.2°; 11.4°±0.2°; 11.6°±0.2°; 12.0°±0.2°; 13.9°±0.2°; 14.4°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; 20.7°±0.2°; and 23.2°±0.2° .... In some embodiments, crystalline form IB of the compound of formula B has an XRPD pattern that includes two or more, three or more, or four or more of the following peaks in 2θ: 6.2°±0.2°; 12.0°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; 19.3°±0.2°; 20.7°±0.2°; 23.2°±0.2°; and 27.1°±0.2°. In some embodiments, crystalline form IB of the compound of formula B has an XRPD pattern that includes two or more, three or more, or four or more of the following peaks in 2θ: 6.2°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; 20.7°±0.2°; and 23.2°±0.2°. In some embodiments, crystalline form IB of the compound of formula B has an XRPD pattern comprising two or more, three or more, or four or more of the following peaks in 2θ: 6.2°±0.2°; 10.4°±0.2°; 11.4°±0.2°; 11.6°±0.2°; 12.0°±0.2°; 13.9°±0.2°; and 14.4°±0.2°.
[0069] In some embodiments, form IB of the compound of formula B is characterized by a DSC thermogram comprising an endothermic peak having a maximum at about 174° C. In some embodiments, crystalline form IB of the compound of formula B has a DSC thermogram substantially as shown in FIG.
[0070] Crystalline Form IIB of the compound of formula B In some embodiments, the crystalline form of the compound of formula B is Form IIB. In some embodiments, the crystalline form IIB of the compound of formula B is anhydrous and ansolvated. This crystalline form can be prepared generally as described in Example 8.
[0071] Crystalline Form IIB of the compound of formula B can be identified, for example, by unique signatures for X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC). In some embodiments, crystalline Form IIB of the compound of formula B is characterized by an XRPD pattern substantially as shown in Figure 12. The peaks of the XRPD pattern are listed in Table 5.
[0072] In some embodiments, crystalline form IIB of the compound of formula B is characterized by an XRPD pattern that includes a peak at 4.2°±0.2° in 2θ. In some embodiments, crystalline form IIB of the compound of formula B is characterized by an XRPD pattern that includes a peak at 7.4°±0.2° in 2θ. In some embodiments, crystalline form IIB of the compound of formula B is characterized by an XRPD pattern that includes a peak at 13.3°±0.2° in 2θ. In some embodiments, crystalline form IIB of the compound of formula B is characterized by an XRPD pattern that includes a peak at 20.1°±0.2° in 2θ. In some embodiments, crystalline form IIB of the compound of formula B is characterized by an XRPD pattern that includes a peak at 17.0°±0.2° in 2θ. In some embodiments, crystalline form IIB of the compound of formula B is characterized by an XRPD pattern that includes a peak at 18.8°±0.2° in 2θ.
[0073] In some embodiments, crystalline form IIB of the compound of formula B has an XRPD pattern comprising the following peaks in 2θ: 4.3°±0.2°; 7.4°±0.2°; 13.3°±0.2°; and 15.3°±0.2°. In some embodiments, crystalline form IIB of the compound of formula B has an XRPD pattern comprising the following peaks in 2θ: 4.3°±0.2°; 7.4°±0.2°; 15.3°±0.2°; 17.0°±0.2°; 18.8°±0.2°; and 20.1°±0.2°. In some embodiments, crystalline form IIB of the compound of formula B has an XRPD pattern comprising the following peaks in 2θ: 4.3°±0.2°; 7.4°±0.2°; 13.3°±0.2°; 15.3°±0.2°; 15.5°±0.2°; 17.0°±0.2°; 17.2°±0.2°; 18.1°±0.2°; 18.8°±0.2°; 19.6°±0.2°; 20.1°±0.2°; 21.4°±0.2°; 23.5°±0.2°; 25.8°±0.2°; 26.2°±0.2°; and 27.3°±0.2°.
[0074] In some embodiments, crystalline Form IIB of the compound of formula B has an XRPD pattern comprising two or more, three or more, or four or more of the following peaks in 2θ: 4.3°±0.2°; 7.4°±0.2°; 13.3°±0.2°; 15.3°±0.2°; 15.5°±0.2°; 17.0°±0.2°; 17.2°±0.2°; 18.1°±0.2°; 18.8°±0.2°; 19.6°±0.2°; 20.1°±0.2°; 21.4°±0.2°; 23.5°±0.2°; 25.8°±0.2°; 26.2°±0.2°; and 27.3°±0.2°. In some embodiments, crystalline form IIB of the compound of formula B has an XRPD pattern including two or more, three or more, or four or more of the following peaks in 2θ: 4.3°±0.2°; 7.4°±0.2°; 13.3°±0.2°; 15.3°±0.2°; 15.5°±0.2°; 17.0°±0.2°; 17.2°±0.2°; 18.8°±0.2°; and 20.1°±0.2°.
[0075] In some embodiments, Form IIB of the compound of formula B is characterized by a DSC thermogram comprising an endothermic peak having a maximum at about 165° C. In some embodiments, crystalline Form IIB of the compound of formula B has a DSC thermogram substantially as shown in FIG.
[0076] Crystalline forms of the compound of formula C The compound of formula C may be isolated in multiple crystalline forms, including, for example, crystalline forms that are anhydrous and / or unsolvated. In some embodiments, the crystalline form of the compound of formula C is anhydrous. In some embodiments, the crystalline form of the compound of formula C is unsolvated. In some embodiments, the crystalline form of the compound of formula C is anhydrous and unsolvated. By "anhydrous" is meant that the crystalline form of the compound of formula C is essentially free of bound water in the crystal lattice structure, i.e., the compound does not form crystalline hydrates.
[0077] In some embodiments, the present application provides a process for preparing a crystalline form of the compound 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide. In some embodiments, the process includes dissolving 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide in a solvent to form a mixture and crystallizing the compound from the mixture.
[0078] In some embodiments, the process further comprises heating the mixture to a temperature of about 70° C. to about 90° C. In some embodiments, the process further comprises cooling the mixture to room temperature.
[0079] In some embodiments, the solvent comprises isopropyl acetate. In some embodiments, the solvent further comprises heptane.
[0080] The present application provides a crystalline form of the compound 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide prepared according to the process set forth herein. In some embodiments, the crystalline form is Form IC as described herein.
[0081] In some embodiments, the crystalline forms of the present invention are substantially isolated. By "substantially isolated" is meant that a particular crystalline form of the compound of formula C is at least partially isolated from impurities. For example, in some embodiments, the crystalline forms of the present invention contain less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 2.5%, less than about 1%, or less than about 0.5% of impurities. Impurities generally include those that are not substantially isolated crystalline forms, including, for example, other crystalline forms and other substances.
[0082] In some embodiments, the crystalline form of the compound of formula C is substantially free of other crystalline forms. The phrase "substantially free of other crystalline forms" means that a particular crystalline form of the compound of formula C contains greater than about 80%, greater than about 90%, greater than about 95%, greater than about 98%, greater than about 99%, or greater than about 99.5% by weight of a particular crystalline form.
[0083] Crystalline Form IC of the compound of formula C In some embodiments, the crystalline form of the compound of formula C is crystalline form IC. In some embodiments, the crystalline form IC of the compound of formula C is anhydrous and anhydrous. The preparation of the compound of formula C is described in Example 9. The crystalline form IC of the compound of formula C can be generally prepared as described in Example 10.
[0084] Crystalline Form IC of the compound of formula C can be identified, for example, by a unique signature for X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC). In some embodiments, crystalline Form IC of the compound of formula C is characterized by an XRPD pattern substantially as shown in Figure 14. The peaks of the XRPD pattern are listed in Table 6.
[0085] In some embodiments, crystalline Form IC of the compound of formula C is characterized by an XRPD pattern including a peak at 6.2°±0.2° in 2θ. In some embodiments, crystalline Form IC of the compound of formula C is characterized by an XRPD pattern including a peak at 11.9°±0.2° in 2θ. In some embodiments, crystalline Form IC of the compound of formula C is characterized by an XRPD pattern including a peak at 16.7°±0.2° in 2θ. In some embodiments, crystalline form IC of the compound of formula C has an XRPD pattern that includes the following peaks in 2θ: 6.2°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; 18.8°±0.2°; 19.9°±0.2°; 20.7°±0.2°; 21.2°±0.2°; 22.3°±0.2°; 23.2°±0.2°; and 27.0°±0.2°. In some embodiments, crystalline form IC of the compound of formula C has an XRPD pattern that includes the following peaks in 2θ: 6.2°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; and 21.2°±0.2°. In some embodiments, crystalline form IC of the compound of formula C has an XRPD pattern comprising the following peaks at 2θ: 6.2°±0.2°; 10.4°±0.2°; 11.3°±0.2°; 11.9°±0.2°; and 12.5°±0.2°.
[0086] In some embodiments, crystalline form IC of compound of formula C has an XRPD pattern including two or more, three or more, or four or more of the following peaks in 2θ: 6.2°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; 18.8°±0.2°; 19.9°±0.2°; 20.7°±0.2°; 21.2°±0.2°; 22.3°±0.2°; 23.2°±0.2°; and 27.0°±0.2°. In some embodiments, crystalline form IC of compound of formula C has an XRPD pattern including two or more, three or more, or four or more of the following peaks in 2θ: 6.2°±0.2°; 10.4°±0.2°; 11.3°±0.2°; 11.9°±0.2°; 12.5°±0.2°; 13.8°±0.2°; 14.4°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; 20.7°±0.2°; and 21.2°±0.2°. In some embodiments, crystalline form IC of the compound of formula C has an XRPD pattern comprising two or more, three or more, or four or more of the following peaks in 2θ: 6.2°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; 20.7°±0.2°; and 21.2°±0.2°.
[0087] In some embodiments, Form IC of the compound of formula C is characterized by a DSC thermogram comprising an endothermic peak having a maximum at about 179° C. In some embodiments, crystalline Form IC of the compound of formula C has a DSC thermogram substantially as shown in FIG.
[0088] How to use The compounds of the invention described herein (e.g., salts and crystalline forms) inhibit the activity of PI3K gamma kinase. Thus, the salts and crystalline forms of the invention described herein can be used in a method of inhibiting PI3K gamma kinase by contacting the kinase. In some embodiments, the salts and crystalline forms of the invention can be used in a method of inhibiting the activity of PI3K gamma in an individual / patient in need of inhibition by administering an effective amount of a salt or crystalline form described herein. In some embodiments, the modulation is inhibition. In some embodiments, the contacting is in vivo. In some embodiments, the contacting is ex vivo. Advantageously, the crystalline forms described herein show better efficacy in animal studies as well as favorable safety and toxicity profiles.
[0089] In some embodiments, the PI3K gamma comprises a mutation. The mutation may be a replacement of one amino acid with another amino acid, or a deletion of one or more amino acids. In such embodiments, the mutation may be in the kinase domain of the PI3K gamma.
[0090] In some embodiments, the salt or crystalline form further inhibits PI3Kδ.
[0091] The salts and crystal forms described herein may be selective. By "selective" it is meant that the salts or crystal forms bind to or inhibit PI3K gamma with greater affinity or potency, respectively, compared to at least one other kinase. In some embodiments, the salts and crystal forms of the present disclosure are selective inhibitors of PI3K gamma over PI3K delta, PI3K alpha, and PI3K beta. In some embodiments, the salts and crystal forms of the present disclosure are selective inhibitors of PI3K gamma over PI3K alpha and PI3K beta. In some embodiments, the selectivity may be at least about 2-fold, 3-fold, 5-fold, 10-fold, or 20-fold over PI3K delta as measured by the assays described herein. In some embodiments, the selectivity may be tested at an ATP concentration of 2 μM for each enzyme. In some embodiments, the selectivity of the salts and crystal forms of the present disclosure may be determined by a cellular assay related to a particular PI3K kinase activity.
[0092] Another aspect of the present disclosure relates to a method of treating a kinase PI3Kγ-related disease or disorder in an individual (e.g., a patient) by administering to the individual in need thereof a therapeutically effective amount or dose of one or more salts or crystalline forms of the present disclosure or a pharmaceutical composition thereof. A PI3Kγ-related disease or disorder can include any disease, disorder, or condition that is directly or indirectly linked to expression or activity of PI3Kγ, including overexpression and / or abnormal activity levels.
[0093] In some embodiments, the disease or disorder is an autoimmune disease or disorder, cancer, a cardiovascular disease, or a neurodegenerative disease.
[0094] In some embodiments, the disease or disorder is lung cancer (e.g., non-small cell lung cancer), melanoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, colon cancer, endometrial cancer, bladder cancer, skin cancer, uterine cancer, renal cancer, gastric cancer, or sarcoma. In some embodiments, the sarcoma is Askin tumor, botryoid sarcoma, chondrosarcoma, Ewing's sarcoma, malignant hemangioendothelioma, malignant nerve sheath tumor, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans, desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), hemangiopericytoma, angiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, or undifferentiated pleomorphic sarcoma.
[0095] In some embodiments, the disease or disorder is mesothelioma or adenocarcinoma. In some embodiments, the disease or disorder is mesothelioma. In some embodiments, the disease or disorder is adrenal carcinoma.
[0096] In some embodiments, the disease or disorder is acute myeloid leukemia (e.g., acute monocytic leukemia), small lymphocytic lymphoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma, actute lymphoblasic T-cell leukemia (T-ALL), cutaneous T-cell lymphoma, large granular lymphocytic leukemia, mature (peripheral) T-cell neoplasm (PTCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma. In some embodiments, the mature (peripheral) T-cell neoplasm (PTCL) is T-cell prolymphocytic leukemia, T-cell granular lymphocytic leukemia, aggressive NK-cell leukemia, mycosis fungoides / Sezary syndrome, naplastic large cell lymphoma (T-cell type), enteropathic T-cell lymphoma, adult T-cell leukemia / lymphoma, or angioimmunoblastic T-cell lymphoma. In some embodiments, the anaplastic large cell lymphoma (ALCL) is systemic ALCL or primary cutaneous ALCL.
[0097] In some embodiments, the disease or disorder is Burkitt's lymphoma, acute myeloblastic leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, hairy cell leukemia, mantle cell lymphoma, small lymphocytic lymphoma, follicular lymphoma, xeroderma pigmentosum, keratoacanthoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, Waldenstrom's macroglobulinemia, prolymphocytic leukemia, acute lymphoblastic leukemia, acute myelogenous ... blastic leukemia, myelofibrosis, mucosa-associated lymphoid tissue (MALT) lymphoma, mediastinal (thymic) large B-cell lymphoma, lymphomatoid granulomatosis, splenic marginal zone lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, plasma cell leukemia, extramedullary plasmacytoma, smoldering myeloma (also known as indolent myeloma), monoclonal gammopathy of undetermined significance (MGUS), or diffuse large B-cell lymphoma.
[0098] MDSCs (myeloid-derived suppressor cells) are a heterogeneous group of immune cells from the myeloid lineage (a family of cells originating from bone marrow stem cells). MDSCs proliferate strongly as a result of altered hematopoiesis in pathological conditions such as chronic infections and cancer. MDSCs are distinct from other myeloid cell types in that they have potent immunosuppressive activity rather than immunostimulatory properties. As with other myeloid cells, MDSCs interact with and regulate the function of other types of immune cells, including T cells, dendritic cells, macrophages, and natural killer cells. In some embodiments, for example, the compounds, etc. described herein may be used in methods related to cancer tissues (e.g., tumors) with high infiltration of MDSCs, including solid tumors with high basal levels of infiltration of macrophages and / or MDSCs.
[0099] In some embodiments, the disease or disorder is Burkitt's lymphoma, acute myeloblastic leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, hairy cell leukemia, mantle cell lymphoma, small lymphocytic lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, Waldenstrom's macroglobulinemia, prolymphocytic leukemia, acute lymphoblastic leukemia, Myelofibrosis, mucosa-associated lymphoid tissue (MALT) lymphoma, mediastinal (thymic) large B-cell lymphoma, lymphomatoid granulomatosis, splenic marginal zone lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, plasma cell leukemia, extramedullary plasmacytoma, smoldering myeloma (also known as indolent myeloma), monoclonal gammopathy of undetermined significance (MGUS), or diffuse large B-cell lymphoma.
[0100] In some embodiments, the non-Hodgkin's lymphoma (NHL) is relapsed NHL, refractory NHL, relapsed follicular NHL, indolent NHL (iNHL), or aggressive NHL (aNHL).
[0101] In some embodiments, the diffuse large B-cell lymphoma is activated B-cell-like (ABC) diffuse large B-cell lymphoma or germinal center B-cell (GCB) diffuse large B-cell lymphoma.
[0102] In some embodiments, the Burkitt lymphoma is endemic Burkitt lymphoma, sporadic Burkitt lymphoma, or Burkitt-like lymphoma.
[0103] In some embodiments, the disease or disorder is rheumatoid arthritis, multiple sclerosis, systemic lupus erythematous, asthma, allergy (e.g., allergic rhinitis), pancreatitis, psoriasis, anaphylaxis, glomerulonephritis, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), thrombosis, meningitis, encephalitis, diabetic retinopathy, benign prostatic hyperplasia, myasthenia gravis, Sjogren's syndrome, osteoarthritis, restenosis, or atherosclerosis.
[0104] In some embodiments, the disease or disorder is cardiac hypertrophy, cardiomyocyte dysfunction, acute coronary syndrome, chronic obstructive pulmonary disease (COPD), chronic bronchitis, elevated blood pressure, ischemia, ischemia-reperfusion, vasoconstriction, anemia (e.g., hemolytic anemia, aplastic anemia, or true erythrocytic anemia), bacterial infection, viral infection, graft rejection, kidney disease, anaphylactic shock fibrosis, skeletal muscle atrophy, skeletal muscle hypertrophy, angiogenesis, sepsis, graft-versus-host disease, allogeneic or xenogeneic transplantation, glomerulosclerosis, progressive renal fibrosis, idiopathic thrombocytopenic purpura (ITP), idiopathic pulmonary fibrosis, autoimmune hemolytic anemia, vasculitis, lupus nephritis, pemphigus, or membranous nephropathy.
[0105] In some embodiments, the disease or disorder is cardiac hypertrophy, cardiomyocyte dysfunction, chronic obstructive pulmonary disease (COPD), elevated blood pressure, ischemia, ischemia-reperfusion, vasoconstriction, anemia (e.g., hemolytic anemia, aplastic anemia, or true erythrocytic anemia), bacterial infection, viral infection, graft rejection, kidney disease, anaphylactic shock fibrosis, skeletal muscle atrophy, skeletal muscle hypertrophy, angiogenesis, sepsis, graft rejection, glomerulosclerosis, progressive renal fibrosis, idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, vasculitis, systemic lupus erythematosus, lupus nephritis, pemphigus, or membranous nephropathy.
[0106] In some embodiments, the disease or disorder is Alzheimer's disease, central nervous system injury, or stroke.
[0107] In some embodiments, the idiopathic thrombocytopenic purpura (ITP) is recurrent ITP or refractory ITP.
[0108] In some embodiments, the vasculitis is Behcet's disease, Cogan's syndrome, giant cell arteritis, polymyalgia rheumatica (PMR), Takayasu's arteritis, Buerger's disease (thromboangiitis obliterans), central nervous system vasculitis, Kawasaki disease, polyarteritis nodosa, Churg-Strauss syndrome, mixed cryoglobulinemic vasculitis (essential or hepatitis C virus (HCV)-induced), Henoch-Schönlein purpura (HSP), hypersensitivity vasculitis, microscopic polyangiitis, Wegener's granulomatosis, or antineutrophil cytoplasmic antibody-associated (ANCA) systemic vasculitis (AASV).
[0109] The disclosure further provides a salt or crystalline form described herein for use in any of the methods described herein.
[0110] The disclosure further provides the use of a crystalline form described herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for use in any of the methods described herein.
[0111] As used herein, the term "contacting" refers to bringing the indicated moieties together in an in vitro system or in vivo system. For example, "contacting" PI3K with a salt or crystalline form of the present disclosure includes administering a crystalline form of the present disclosure to an individual or patient, such as a human, having PI3K, and for example, introducing a salt or crystalline form of the present disclosure into a sample containing a cell preparation or purified preparation containing PI3K.
[0112] It is believed that the salts and crystalline forms provided herein, or any of the embodiments thereof, may have a sufficient pharmacological profile and promising biopharmaceutical properties, such as toxicological profile, metabolic and pharmacokinetic properties, solubility, and permeability. It is understood that determining suitable biopharmaceutical properties is within the knowledge of one of ordinary skill in the art, such as determining cytotoxicity or inhibition of a given target or channel in a cell to determine potential toxicity.
[0113] As used herein, the terms "individual" or "patient", used interchangeably, refer to any animal, including a mammal, preferably a mouse, rat, other rodent, rabbit, dog, cat, pig, cow, sheep, horse, or primate, most preferably a human.
[0114] As used herein, the phrase "therapeutically effective amount" refers to that amount of active salt, crystalline form, or pharmaceutical agent that elicits the biological or pharmacological response sought in a tissue, system, animal, individual, or human by a researcher, veterinarian, physician, or other clinician.
[0115] As used herein, the term "treating" or "treatment" can refer to one or more of: (1) inhibiting a disease, e.g., inhibiting a disease, condition, or disorder in an individual experiencing or exhibiting the symptoms or symptomology of the disease, condition, or disorder (i.e., halting further progression of the symptoms and / or symptomology), and (2) ameliorating a disease, condition, or disorder in an individual experiencing or exhibiting the symptoms or symptomology of the disease, condition, or disorder (i.e., reversing the symptoms and / or symptomology), such as reducing the severity of the disease.
[0116] In some embodiments, the salts and crystalline forms of the invention may be useful in preventing the onset of, or reducing the risk of developing, any of the diseases mentioned herein, for example, in preventing the onset of, or reducing the risk of developing, a disease, condition, or disorder in an individual who may be predisposed to the disease, condition, or disorder but has not yet experienced or exhibited the symptoms or symptomology of the disease.
[0117] Combination therapy I. Immune checkpoint therapy In some embodiments, the PI3K gamma inhibitors provided herein can be used in combination with one or more immune checkpoint inhibitors for the treatment of cancer as described herein. In one embodiment, the combination with one or more immune checkpoint inhibitors as described herein can be used for the treatment of melanoma. The salts and crystalline forms of the present disclosure can be used in combination with one or more immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD20, CD28, CD40, CD122, CD96, CD73, CD47, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, HPK1, CD137 (also known as 4-1BB), ICOS, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, TIGIT, PD-1, PD-L1, and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR, and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, TIGIT, and VISTA. In some embodiments, the salts and crystalline forms of the disclosure provided herein may be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors, and TGFR beta inhibitors.
[0118] In some embodiments, the PI3Kγ inhibitors provided herein may be used in combination with one or more agonists of immune checkpoint molecules, such as OX40, CD27, OX40, GITR, and CD137 (also known as 4-1BB).
[0119] In some embodiments, the inhibitor of an immune checkpoint molecule is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
[0120] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-1, for example, an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), durvalumab (Imfinzi®), pidilizumab, SHR-1210, PDR001, MGA012, PDR001, AB122, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD1 antibody is pembrolizumab. In some embodiments, the anti-PD-1 monoclonal antibody is MGA012. In some embodiments, the anti-PD1 antibody is SHR-1210. Other anti-cancer agent(s) include antibody therapeutics such as 4-1BB (e.g., urelumab, utomirumab).
[0121] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-L1, such as an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A or MEDI4736.
[0122] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1 and PD-L1, e.g., an anti-PD-1 / PD-L1 monoclonal antibody. In some embodiments, the anti-PD-1 / PD-L1 is MCLA-136.
[0123] In some embodiments, the inhibitor is MCLA-145.
[0124] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CTLA-4, such as an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884, or CP-675,206.
[0125] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of LAG3, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016, LAG525, or INCAGN2385.
[0126] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of TIM3, such as an anti-TIM3 antibody. In some embodiments, the anti-TIM3 antibody is INCAGN2390, MBG453, or TSR-022.
[0127] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of GITR, such as an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, or MEDI1873.
[0128] In some embodiments, the inhibitor of immune checkpoint molecule is an agonist of OX40, such as an OX40 agonist antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, or BMS-986178. In some embodiments, the OX40L fusion protein is MEDI6383.
[0129] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD20, such as an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab.
[0130] The salts and crystalline forms of the present disclosure may be used in combination with bispecific antibodies, in some embodiments, one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, OX40, TIM3, LAG3, CD137, ICOS, CD3, or a TGFβ receptor.
[0131] In some embodiments, the PI3K gamma inhibitors provided herein can be used in combination with one or more metabolic enzyme inhibitors.In some embodiments, the metabolic enzyme inhibitor is an inhibitor of IDO1, TDO, or arginase.Examples of IDO1 inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099, and LY338196.
[0132] As provided throughout, the additional compounds, inhibitors, agents, etc. may be combined with the present compounds in a single or sequential dosage form, or they may be administered simultaneously or sequentially as separate dosage forms.
[0133] II. Cancer Treatment Cancer cell growth and survival can be affected by multiple signal transduction pathways.Therefore, it is useful to combine different enzyme / protein / receptor inhibitors that show different selectivity in the target that regulates their activity to treat such conditions.Targeting two or more signal transduction pathways (or two or more biological molecules involved in a given signal transduction pathway) can reduce the possibility of drug resistance occurring in cell populations and / or reduce the toxicity of treatment.
[0134] The salts and crystalline forms of the present disclosure may be used in combination with one or more other enzyme / protein / receptor inhibitors or one or more therapies for the treatment of diseases such as cancer. Examples of diseases and indications treatable with combination therapy include those described herein. Examples of cancer include solid tumors and liquid tumors such as blood cancers.
[0135] For example, one or more additional pharmaceutical agents, such as chemotherapeutic agents, anti-inflammatory agents, steroids, immunosuppressants, cancer immunotherapeutic agents, metabolic enzyme inhibitors, chemokine receptor inhibitors, and phosphatase inhibitors, as well as targeted therapies, such as Bcr-Abl, Flt-3, EGFR, HER2, JAK, c-MET, VEGFR, PDGFR, c-Kit, IGF-1R, RAF, and FAK kinase inhibitors, such as those described in WO2006 / 056399. Other agents, such as therapeutic antibodies, may be used in combination with the salts and crystalline forms of the present disclosure for the treatment of PI3K-related diseases, disorders, or conditions. The one or more additional pharmaceutical agents may be administered to the patient simultaneously or sequentially.
[0136] For example, the salts and crystalline forms as disclosed herein can be combined with one or more inhibitors of the following kinases: Akt1, Akt2, Akt3, TGF-βR, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFαR for the treatment of cancer and other diseases or disorders described herein. , PDGFβR, CSFIR, KIT, FLK-II, KDR / FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3 , VEGFR / Flt2, Flt4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK, and B-Raf. Non-limiting examples of inhibitors that can be combined with the salts and crystalline forms of the present disclosure for the treatment of cancer and other diseases and disorders described herein include FGFR inhibitors (FGFR1, FGFR2, FGFR3, or FGFR4, e.g., INCB54828, INCB62079, and INCB63904), JAK inhibitors (JAK1 and / or JAK2, e.g., ruxolitinib, baricitinib, or INCB39110), IDO inhibitors (e.g., epacadostat, NLG919, or BMS-986205), LSD1 inhibitors (e.g., INCB59872 and INCB63904), and / or IL-1 inhibitors (e.g., IL-1 inhibitors, e ... 0003), TDO inhibitors, PI3K-delta inhibitors (e.g., INCB50797 and INCB50465), Pim inhibitors, CSF1R inhibitors, TAM receptor tyrosine kinases (Tyro-3, Axl, and Mer), histone deacetylase inhibitors (HDACs) such as HDAC8 inhibitors, angiogenesis inhibitors, interleukin receptor inhibitors, bromo and extra terminal family member inhibitors (e.g., bromo domain inhibitors or BET inhibitors such as INCB54329 and INCB57643), and adenosine receptor antagonists, or combinations thereof.
[0137] In some embodiments, the salts and crystalline forms described herein are administered with a PI3Kδ inhibitor. In some embodiments, the salts and crystalline forms described herein are administered with a JAK inhibitor. In some embodiments, the salts and crystalline forms described herein are administered with a JAK1 or JAK2 inhibitor (e.g., baricitinib or ruxolitinib). In some embodiments, the salts and crystalline forms described herein are administered with a JAK1 inhibitor. In some embodiments, the salts and crystalline forms described herein are administered with a JAK1 inhibitor that is more selective than JAK2.
[0138] Examples of antibodies for use in combination therapy include, but are not limited to, trastuzumab (e.g., anti-HER2), ranibizumab (e.g., anti-VEGF-A), bevacizumab (trade name Avastin, e.g., anti-VEGF), panitumumab (e.g., anti-EGFR), cetuximab (e.g., anti-EGFR), Rituxan (anti-CD20), and antibodies against c-MET.
[0139] One or more of the following agents may be used in combination with the salts and crystalline forms of the present disclosure, which are presented as a non-limiting list: cytostatics, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilone, tamoxifen, 5-fluorouracil, methotrexate, temozolomide, cyclophosphamide, SCH66336, R115777, L778,123, BMS214662, IRESSA™ (gefitinib), TARCEVA™ (erlotinib), antibodies against EGFR, intron, ara-C, adriamycin, cytoxan, gemcitabine, uracil masterbate. amide, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN (oxaliplatin), pentostatin, vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, teniposide 17. alpha-.- Ethinyl estradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromestanolone propionate, testolactone, megstrol acetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide, flutamide, toremifene, goserelin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, navelbene, anastrazole, letrazole, capecitabine, reloxafine, droloxafine, hexamethylmelamine, avastin, HERCEPTIN (trademark) Mab), BEXXAR™ (tositumomab), VELCADE™ (bortezomib), ZEVALIN™ (ibritumomab tiuxetan), TRISENOX™ (arsenic trioxide), XELODA™ (capecitabine), vinorelbine, porfimer, ERBITUX™ (cetuximab), thiotepa, altretamine, melphalan, trastuzumab, relozoo le, fulvestrant, exemestane, ifosfomide, rituximab, C225 (cetuximab), Campath (alemtuzumab), clofarabine, cladribine, afidicolone, rituxan, sunitinib, dasatinib, tezacitabine, Sml1, fludarabine, pentostatin, triapin, didox, trimidox, amidox, 3-AP, and MDL-101,731.
[0140] The salts and crystalline forms of the present disclosure can further be used in combination with other methods of treating cancer, for example, by chemotherapy, radiation therapy, tumor-targeted therapy, adjuvant therapy, immunotherapy, or surgery. Examples of immunotherapy include cytokine treatment (e.g., interferon, GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccines, monoclonal antibodies, adoptive T cell transfer, Toll receptor agonists, STING agonists, oncolytic virus therapy, and immunomodulatory small molecules, including thalidomide or JAK1 / 2 inhibitors, etc. The salts and crystalline forms can be administered in combination with one or more anti-cancer agents, for example, chemotherapeutic agents. Examples of chemotherapy drugs include abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin, bortezomib, bortezomib, intravenous busulfan, oral busulfan, calcitidine, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erbicin, Lotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, indiragi Terferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, mechlorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab,The present invention includes any of olapariboxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, rucaparib, streptozocin, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, niraparib, veliparib, talazoparib, and zoledronate.
[0141] Additional examples of chemotherapeutic agents include proteosome inhibitors (eg, bortezomib), thalidomide, revlimid, and DNA damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.
[0142] Exemplary steroids include corticosteroids such as dexamethasone or prednisone.
[0143] Exemplary Bcr-Abl inhibitors include imatinib mesylate (GLEEVAC™), nilotinib, dasatinib, bosutinib, and ponatinib, and pharmaceutically acceptable salts. Other exemplary suitable Bcr-Abl inhibitors include the genera and species of compounds disclosed in U.S. Patent No. 5,521,184, WO04 / 005281, and U.S. Patent No. 60 / 578,491, and pharmaceutically acceptable salts thereof.
[0144] Exemplary suitable Flt-3 inhibitors include midostaurin, lestaurtinib, linifanib, sunitinib, sunitinib maleate, sorafenib, quizartinib, crenolanib, pacritinib, tandutinib, PLX3397, and ASP2215, and pharmaceutically acceptable salts thereof. Other exemplary suitable Flt-3 inhibitors include compounds as disclosed in WO03 / 037347, WO03 / 099771, and WO04 / 046120, and pharmaceutically acceptable salts thereof.
[0145] Exemplary suitable RAF inhibitors include dabrafenib, sorafenib, and vemurafenib, and pharmaceutically acceptable salts thereof. Other exemplary suitable RAF inhibitors include compounds as disclosed in WO00 / 09495 and WO05 / 028444, and pharmaceutically acceptable salts thereof.
[0146] Exemplary suitable FAK inhibitors include VS-4718, VS-5095, VS-6062, VS-6063, BI853520, and GSK2256098, and pharma- ceutically acceptable salts thereof. Other exemplary suitable FAK inhibitors include those compounds disclosed in WO04 / 080980, WO04 / 056786, WO03 / 024967, WO01 / 064655, WO00 / 053595, and WO01 / 014402, and pharma- ceutically acceptable salts thereof.
[0147] In some embodiments, the salts and crystalline forms of the present disclosure can be used in combination with one or more other kinase inhibitors, including imatinib, particularly to treat patients who are resistant to imatinib or other kinase inhibitors.
[0148] In some embodiments, the salts and crystalline forms of the present disclosure can be used in combination with chemotherapeutic agents in the treatment of cancer, and can improve therapeutic response compared to the response to the chemotherapeutic agent alone, without exacerbating its toxic effects. In some embodiments, the salts and crystalline forms of the present disclosure can be used in combination with chemotherapeutic agents provided herein. For example, additional pharmaceutical agents used in the treatment of multiple myeloma can include, but are not limited to, melphalan, melphalan + prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib). Further additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF, and FAK kinase inhibitors. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of alkylating agents include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM). Additive or synergistic effects are desirable outcomes of combining a PI3K inhibitor of the present disclosure with an additional agent.
[0149] In some embodiments, the salts and crystalline forms of the present disclosure can be used in combination with inhibitors of JAK or PI3Kδ.
[0150] The agents may be combined with the compound in a single or consecutive dosage form, or the agents may be administered simultaneously or sequentially as separate dosage forms.
[0151] The salts and crystalline forms of the present disclosure can be used in combination with one or more other inhibitors or one or more therapies for the treatment of infectious diseases, including viral, bacterial, fungal, or parasitic infections.
[0152] In some embodiments, a corticosteroid such as dexamethasone is administered to a patient in combination with a compound of the present disclosure, where the dexamethasone is administered intermittently rather than continuously.
[0153] The salts and crystalline forms of the present disclosure described herein can be combined with another immunogen, such as cancer cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines. Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gp100, MAGE antigens, Trp-2, MARTI, and / or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.
[0154] The salts and crystalline forms of the present disclosure described herein can be used in combination with vaccination protocols for the treatment of cancer. In some embodiments, tumor cells are transduced to express GM-CSF. In some embodiments, tumor vaccines include proteins from viruses involved in human cancers, such as human papillomavirus (HPV), hepatitis viruses (HBV and HCV), and Kaposi's herpes sarcoma virus (KHSV). In some embodiments, the salts and crystalline forms of the present disclosure can be used in combination with tumor-specific antigens, such as heat shock proteins isolated from the tumor tissue itself. In some embodiments, the salts and crystalline forms can be combined with dendritic cell immunization to activate a strong anti-tumor response.
[0155] The salts and crystalline forms of the present disclosure can be used in combination with bispecific macrocyclic peptides that target Fe alpha or Fe gamma receptor expressing effector cells to tumor cells. The salts and crystalline forms of the present disclosure can also be used in combination with macrocyclic peptides that activate the host's immune responsiveness.
[0156] In some further embodiments, combinations of the disclosed salts and crystalline forms with other therapeutic agents can be administered to a patient before, during, and / or after bone marrow or stem cell transplantation. The disclosed salts and crystalline forms can be used in combination with bone marrow transplantation for the treatment of various tumors of hematopoietic origin.
[0157] The salts and crystalline forms can be used in combination with vaccines to stimulate immune responses against pathogens, toxins, and self-antigens. Examples of pathogens for which this therapeutic approach may be particularly useful include those for which there is currently no effective vaccine or for which conventional vaccines are not fully effective. These include, but are not limited to, HIV, Hepatitis (types A, B, and C), influenza, herpes, Giardia, malaria, Leishmania, Staphylococcus aureus, and Pseudomonas Aeruginosa.
[0158] Viruses causing infectious diseases treatable by the methods of the present disclosure include, but are not limited to, human papillomavirus, influenza, hepatitis A, B, C or D virus, adenovirus, poxvirus, herpes simplex virus, human cytomegalovirus, severe acute respiratory syndrome virus, Ebola virus, measles virus, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein-Barr virus), flavivirus, echovirus, rhinovirus, coxsackievirus, cornovirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, infectious virus, poliovirus, rabies virus, JC virus, and arboviral encephalitis virus.
[0159] Pathogenic bacteria causing infections treatable by the methods of the present disclosure include, but are not limited to, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme burgdorferi.
[0160] Pathogenic fungi causing infections treatable by the methods of the present disclosure include, but are not limited to, Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, and Histoplasma capsulatum. Examples of pathogenic parasites causing infections treatable by the methods of the present disclosure include, but are not limited to, Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
[0161] Methods for safely and effectively administering most of these chemotherapeutic agents are known to those of skill in the art, and their administration is described in the standard literature. For example, the administration of many chemotherapeutic agents is described in the "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosure of which is incorporated herein by reference as if set forth in its entirety.
[0162] Pharmaceutical Preparations and Dosage Forms When used as a formulation, the compounds of the present disclosure (e.g., salts and crystalline forms) can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art and can be administered by various routes depending on whether local or systemic treatment is desired and the area to be treated. Administration can be topical (including transdermal, epidermal, ocular, and mucosal delivery, including intranasal, vaginal, and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral, or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion, or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose or can be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
[0163] The present disclosure also includes pharmaceutical compositions that contain, as an active ingredient, a compound of the present disclosure or a pharma- ceutically acceptable salt thereof in combination with one or more pharma- ceutical acceptable carriers (excipients). In some embodiments, the compositions are suitable for topical administration. In preparing the compositions of the present disclosure, the active ingredient is typically mixed with an excipient, diluted by an excipient, or enclosed within such a carrier, for example, in the form of a capsule, sachet, paper, or other container. When an excipient functions as a diluent, it can be a solid, semi-solid, or liquid substance that acts as a vehicle, carrier, or medium for the active ingredient. Thus, the composition can be in the form of a tablet, pill, powder, lozenge, sachet, cachet, elixir, suspension, emulsion, solution, syrup, aerosol (as a solid or liquid medium), for example, an ointment containing up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
[0164] When preparing formulation, active compound can be pulverized to obtain suitable particle size before being combined with other components.If active compound is substantially insoluble, it can be pulverized to a particle size of less than 200 mesh.If active compound is substantially water-soluble, particle size can be adjusted by pulverization to provide substantially uniform distribution in formulation, for example, about 40 mesh.
[0165] The compounds of the present disclosure can be milled using known milling procedures, such as wet milling, to obtain particle sizes suitable for tableting and other types of formulations.Finely divided (nanoparticulate) preparations of the compounds of the present disclosure can be prepared by processes known in the art.See, for example, International Application No. WO2002 / 000196.
[0166] Examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methylcellulose.The formulation can additionally include lubricants such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preservatives such as methyl benzoate and propyl hydroxybenzoate; sweeteners; and flavoring agents.The composition of the present disclosure can be formulated to provide quick, sustained, or delayed release of active ingredient after administration to a patient by adopting procedures known in the art.
[0167] The compositions can be formulated in unit dosage form, each dosage containing from about 5 to about 1000 mg (1 g), more usually about 100 to about 500 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to produce a desired therapeutic effect in association with a suitable pharmaceutical excipient.
[0168] In some embodiments, compositions of the present disclosure contain about 5 to about 50 mg of active ingredient. One of skill in the art will appreciate that this embodies compositions containing about 5 to about 10, about 10 to about 15, about 15 to about 20, about 20 to about 25, about 25 to about 30, about 30 to about 35, about 35 to about 40, about 40 to about 45, or about 45 to about 50 mg of active ingredient.
[0169] In some embodiments, compositions of the present disclosure contain about 50 to about 500 mg of active ingredient. One of skill in the art will appreciate that this embodies compositions containing about 50 to about 100, about 100 to about 150, about 150 to about 200, about 200 to about 250, about 250 to about 300, about 350 to about 400, or about 450 to about 500 mg of active ingredient.
[0170] In some embodiments, the compositions of the present disclosure contain about 500 to about 1000 mg of active ingredient. One of skill in the art will appreciate that this embodies compositions containing about 500 to about 550, about 550 to about 600, about 600 to about 650, about 650 to about 700, about 700 to about 750, about 750 to about 800, about 800 to about 850, about 850 to about 900, about 900 to about 950, or about 950 to about 1000 mg of active ingredient.
[0171] Similar dosages of the compounds described herein may be used in the methods and uses of the present disclosure.
[0172] The active compounds can be effective over a wide dosage range and are generally administered in a pharmacologic effective amount. However, it will be understood that the amount of compound actually administered will usually be determined by the physician depending on the relevant circumstances, including the condition to be treated, the route of administration selected, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
[0173] To prepare solid compositions such as tablets, the main active ingredient is mixed with pharmaceutical excipients to form a solid preformulation composition containing a homogenous mixture of the compounds of the present disclosure.When these preformulation compositions are referred to as homogenous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be easily subdivided into equally effective unit dosage forms such as tablets, pills, and capsules.The solid preformulation is then subdivided into unit dosage forms of the type described above, for example, containing about 0.1 to about 1000 mg of the active ingredient of the present disclosure.
[0174] The tablets or pills of the present disclosure can be coated or otherwise compounded to provide a dosage form that provides the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that resists disintegration in the stomach and allows the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, including a number of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.
[0175] Liquid forms into which the compounds and compositions of the present disclosure may be incorporated for oral administration or by injection include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
[0176] Compositions for inhalation or insufflation include solutions and suspensions in pharma- ceutically acceptable aqueous or organic solvents, or mixtures thereof, as well as powders. Liquid or solid compositions may contain suitable pharma- ceutically acceptable excipients as described above. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device, or the nebulizing device may be attached to a face mask, obturator, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered orally or nasally from a device that delivers the formulation in an appropriate manner.
[0177] Topical formulations may include one or more conventional carriers. In some embodiments, ointments may contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white petrolatum, and the like. The carrier composition of creams may be based on water in combination with glycerol and one or more other components, for example, glycerol monostearate, PEG-glycerol monostearate, and cetylstearyl alcohol. Gels may be formulated using isopropyl alcohol and water, suitably combined with other components, for example, glycerol, hydroxyethylcellulose, and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2, or at least about 5% by weight of a compound of the present disclosure. Topical formulations may suitably be packaged in, for example, 100 g tubes, optionally associated with instructions for the treatment of a selected indication, for example, psoriasis or other skin conditions.
[0178] The amount of compound or composition administered to a patient will vary depending on what is being administered, the purpose of the administration, such as prophylaxis or treatment, the condition of the patient, the method of administration, etc. In therapeutic applications, the compositions may be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. The effective dose will depend on the condition of the disease being treated, as well as the judgment of the attending clinician, based on factors such as the severity of the disease, the age, weight, and general health of the patient.
[0179] The compositions administered to a patient may be in the form of pharmaceutical compositions described above. These compositions may be sterilized by conventional sterilization techniques or may be sterile filtered. Aqueous solutions may be packaged or lyophilized for use as is, although lyophilized preparations are combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations is typically 3-11, more preferably 5-9, and most preferably 7-8. It is understood that certain use of the aforementioned excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
[0180] The therapeutic dosage of the compounds of the present disclosure may vary depending, for example, on the particular application for which the treatment is made, the manner in which the compound is administered, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of the compounds of the present disclosure in a pharmaceutical composition may vary depending on several factors, including the dosage amount, chemical properties (e.g., hydrophobicity), and route of administration. For example, the compounds of the present disclosure may be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w / v of the compound for parenteral administration. Some typical dosage ranges are about 1 μg / kg to about 1 g / kg of body weight per day. In some embodiments, the dosage range is about 0.01 mg / kg to about 100 mg / kg of body weight per day. The dosage may depend on such variables as the type and extent of progression of the disease or disorder, the overall health of the particular patient, the relative biological effectiveness of the selected compound, the excipient formulation, and its route of administration. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
[0181] The compositions of the present disclosure may further comprise one or more additional pharmaceutical agents, such as chemotherapeutic agents, steroids, anti-inflammatory compounds, or immunosuppressants, examples of which are listed herein.
[0182] Labeled Compounds and Assay Methods Another aspect of the present disclosure relates to the labeled compounds (e.g., salts and crystalline forms) of the present disclosure that may be useful in both in vitro and in vivo assays, as well as imaging techniques, to locate and quantify PI3K in tissue samples, including humans, and to identify PI3K ligands, by the inhibitory binding of the labeled compounds (radiolabeled, fluorescently labeled, etc.). Substitution of one or more atoms of the compounds of the present disclosure may also be useful in generating differentiated ADME (adsorption, distribution, metabolism, and excretion). Thus, the present disclosure includes PI3K assays that contain such labeled or substituted compounds.
[0183] The present disclosure further includes isotopically labeled compounds of the present disclosure. An "isotopically" or "radiolabeled" compound is a compound of the present disclosure in which one or more atoms have been replaced or substituted with an atom having an atomic mass or mass number different from that typically found in nature (i.e., naturally occurring). Suitable radionuclides that can be incorporated into the compounds of the present disclosure include: 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 18 F, 35 S, 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 I, 124 I, 125 I, and 131 For example, one or more hydrogen atoms in the compounds of the present disclosure may be replaced by a deuterium atom (e.g., C 1~6 One or more hydrogen atoms of an alkyl group can be optionally replaced with a deuterium atom, such as replacing -CH with -CD.) In some embodiments, the alkyl groups of the formulas and / or forms disclosed herein can be all deuterated.
[0184] One or more constituent atoms of the compounds presented herein may be replaced or substituted with an isotope of the atom at natural or non-natural abundance. In some embodiments, the compounds contain at least one deuterium atom. For example, one or more hydrogen atoms in the compounds presented herein may be replaced or substituted with a deuterium atom (e.g., C 1-6One or more hydrogen atoms of the alkyl group may be replaced with a deuterium atom, such as replacing -CH3 with -CD3). In some embodiments, the compound contains two or more deuterium atoms. In some embodiments, the compound contains 1, 1-2, 1-3, 1-4, 1-5, or 1-6 deuterium atoms. In some embodiments, all hydrogen atoms in the compound may be replaced or substituted by deuterium atoms.
[0185] In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 hydrogen atoms bonded to carbon atoms of any Formula A substituent are each optionally replaced by a deuterium atom.
[0186] Synthetic methods for incorporating isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry by Alan F. Thomas (New York, NY, Appleton-Century-Crofts, 1971; The Renaissance of H / D Exchange by Jens Atzrodt, Volker Derdau, Thorsten Fey and Jochen Zimmermann, Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistry of Isotopic Labelling by James R. Hanson, Royal Society of Chemistry, 2011). Isotopically labeled compounds can be used in a variety of studies, such as NMR spectroscopy, metabolic experiments, and / or assays.
[0187] Substitution with heavier isotopes such as deuterium may provide certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and may therefore be preferred in some circumstances. (See, for example, A. Kerekes et.al. J. Med. Chem. 2011, 54, 201-210; R. Xu et.al. J. Label Compd. Radiopharm. 2015, 58, 308-312). In particular, substitution at one or more metabolic sites may provide one or more of the therapeutic advantages.
[0188] The radionuclide that is incorporated into the radiolabeled compound will depend on the particular application of that radiolabeled compound. For example, for in vitro PI3K labeling and competition assays: 3 H, 14 C. 82 Br, 125 I, 131 I, or 35 Compounds incorporating S may be useful. For imaging applications using radiation, 11 C. 18 F, 125 I, 123 I, 124 I, 131 I, 75 Br, 76 Br, or 77 Br may be useful.
[0189] By "radiolabel" or "labeled compound" is understood a compound that incorporates at least one radionuclide. In some embodiments, the radionuclide is 3 H, 14 C. 125 I, 35 S, and 82 Br.
[0190] The present disclosure can further include synthetic methods for incorporating radioisotopes into the compounds of the present disclosure. Synthetic methods for incorporating radioisotopes into organic compounds are well known in the art, and those skilled in the art will readily recognize methods that are applicable to the compounds of the present disclosure.
[0191] The labeled compounds of the present disclosure can be used in screening assays to identify / assess compounds. For example, a newly synthesized or identified labeled compound (i.e., a test compound) can be evaluated for its ability to bind to PI3K by monitoring its concentration change when contacted with PI3K through tracking of the label. For example, a test compound (labeled) can be evaluated for its ability to reduce the binding of another compound (i.e., a standard compound) that is known to bind to PI3K. Thus, the ability of a test compound to compete with a standard compound for binding to PI3K is directly correlated to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and the test compound is not labeled. Thus, to evaluate the competition between the standard compound and the test compound, the concentration of the labeled standard compound is monitored, thereby ascertaining the relative binding affinity of the test compound.
[0192] kit The present disclosure also includes pharmaceutical kits, useful, for example, in the treatment or prevention of PI3K-related diseases or disorders, such as cancer, that include one or more containers housing a pharmaceutical composition comprising a therapeutically effective amount of the salts and crystalline forms of the present disclosure. As will be apparent to one of skill in the art, such kits can optionally further include one or more of a variety of conventional pharmaceutical kit components, such as, for example, a container with one or more pharma-ceutically acceptable carriers, additional containers, etc. Instructions, either as an insert or label, indicating the amounts of components to be administered, administration guidelines, and / or guidelines for mixing the components, can also be included in the kit.
[0193] The present invention will be described in more detail with specific examples.The following examples are provided for illustrative purposes and are not intended to limit the present invention in any way.Those skilled in the art will easily recognize various non-critical parameters that can be changed or modified to essentially produce the same results.The salts and crystalline forms of the examples have been found to be PI3K gamma inhibitors by at least one assay described herein. EXAMPLES
[0194] Preparative LC-MS purification of some of the prepared compounds was carried out on a Waters mass fractionation system. The basic equipment settings, protocols, and control software for the operation of these systems are described in detail in the literature (see, for example, "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004)). The isolated compounds were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity analysis under the following conditions: Instrument: Agilent 1100 series, LC / MSD; Column: Waters Sunfire™ C 18 5 μm, 2.1×50 mm, buffer: mobile phase A: 0.025% TFA in water and mobile phase B: acetonitrile; gradient from 2% to 80% B in 3 min at a flow rate of 2.0 mL / min.
[0195] Some of the prepared compounds were also separated on a preparative scale by reversed-phase high performance liquid chromatography (RP-HPLC) with MS detection or flash chromatography (silica gel) as shown in the examples. Typical preparative reversed-phase high performance liquid chromatography (RP-HPLC) column conditions are as follows: Purification at pH=2: Waters Sunfire™ C 18 , 5μm, 30×100mm or Waters XBridge™ C 18 , 5 μm, 30×100 mm column, elution with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; flow rate was 60 mL / min, and separation gradient was optimized for each compound using Compound Specific Method Optimization protocols as described in the literature (see, e.g., “Preparative LCMS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)).
[0196] pH=10 purification: Waters XBridge (trademark) C 18 5 μm, 30×100 mm column, elution with mobile phase A: 0.1% NH4OH in water and mobile phase B: acetonitrile; flow rate was 60 mL / min, separation gradient was optimized for each compound using Compound Specific Method Optimization protocol as described in literature (see, e.g., “Preparative LCMS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)).
[0197] In the following examples, X-ray powder diffraction analysis was performed on a Bruker D8 Advance EC X-ray powder diffractometer (XRPD) instrument with the following parameters: Cu source at 1.5418 Å and LYNXEY E™ detector and X-ray power of 40 KV, 25 mA. Sample powder was dispersed in a zero background sample holder. General measurement conditions were: start angle -3°; end angle -30°; sample collection -0.015 degrees; and scan speed -2 degrees / min.
[0198] Differential scanning calorimetry (DSC) was performed on a TA Instrument differential scanning calorimeter equipped with an autosampler, Discovery DSC2500. Typical experimental conditions were: 20–300 °C at 10 °C / min, nitrogen gas flow of 50 mL / min, using aluminum sample pans.
[0199] Thermogravimetric analysis (TGA) was performed on a TA Instruments Thermogravimetric Analyzer TGA5500 equipped with an autosampler under the following conditions: 10° C. / min ramp from 25° C. to 600° C.; nitrogen gas at 25 mL / min balance purge flow; and platinum sample pans.
[0200] Example 1. 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide [ka] Step 1. 1-(3-bromo-4-methylphenyl)-2,2,2-trifluoroethan-1-ol [ka] A solution of 3-bromo-4-methylbenzaldehyde (6.51 g, 32.7 mmol) [Aldrich, 565334] in tetrahydrofuran (65.4 mL) was cooled to 0° C. and treated with trimethyl(trifluoromethyl)silane (6.28 mL, 42.5 mmol). The yellow mixture was treated with 1.0 M tetrabutylammonium fluoride in tetrahydrofuran (0.654 mL, 0.654 mmol) at 0° C. and stirred at 0° C. for several minutes. The ice bath was removed and the resulting reaction mixture was stirred for 1.5 hours. The reaction mixture was cooled back to 0° C. and treated with water (6.48 mL, 360 mmol) and 1.0 M tetrabutylammonium fluoride in tetrahydrofuran (6.54 mL, 6.54 mmol). The ice bath was removed and the reaction mixture was stirred at ambient temperature for 30 minutes. The yellow reaction mixture was diluted with brine (150 mL) and extracted with ethyl acetate (200 mL). The organic layer was washed with saturated ammonium chloride (100 mL), dried over sodium sulfate, filtered, and concentrated to give a tan oil. Purification by flash column chromatography using methyl tert-butyl ether (MTBE) in hexanes (0% to 50%) gave the desired product (8.42 g, 95.7%) as a yellow oil. C9H7BrF3(M-OH) + LCMS for: m / z = 251.0, 253.0; Found: 250.9, 252.8.
[0201] Step 2. 1-(3-bromo-4-methylphenyl)-2,2,2-trifluoroethan-1-one [ka] A mixture of 1-(3-bromo-4-methylphenyl)-2,2,2-trifluoroethan-1-ol (8.41 g, 31.3 mmol) in dichloromethane (125 mL) at 0° C. was treated with Dess-Martin periodinane (19.9 g, 46.9 mmol) and stirred at RT for 2.5 h. The reaction mixture was concentrated (by rotary evaporation with the water bath set at 30° C.) to an oily solid, which was diluted with diethyl ether (200 mL) to precipitate more solid. The mixture was filtered through Celite® and the Celite® was rinsed with additional diethyl ether (200 mL). The filtrate was washed with saturated sodium bicarbonate solution (3×200 mL) and brine, dried over sodium sulfate, filtered, and concentrated to give an oily solid. The oily solid was partitioned between diethyl ether (150 mL) and water (100 mL). The organic layer was separated, washed with saturated sodium bicarbonate solution (2×75 mL) and brine, dried over sodium sulfate, filtered and concentrated to give the desired product (7.93 g, 95.0%) as an oil which was used without further purification. C9H7BrF3O (M+H) + LCMS for: m / z = 267.0, 269.0; Found: 267.1, 268.9.
[0202] Step 3. 2-(3-bromo-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanenitrile [ka] A solution of 1-(3-bromo-4-methylphenyl)-2,2,2-trifluoroethan-1-one (7.92 g, 29.7 mmol) in dichloromethane (29.7 mL) was treated with trimethylsilyl cyanide (8.70 mL, 65.2 mmol), potassium cyanide (0.290 g, 4.45 mmol), and 18-crown-6 (0.290 g, 1.10 mmol) and stirred for 1 h. Due to an exotherm following the addition of 18-crown-6, the reaction was cooled in an ice bath. The reaction mixture was concentrated (by rotary evaporation with a water bath set at 28° C.) to give a red-brown solid. The solid was dissolved in THF (29.6 mL), cooled to 0° C., treated with 1.8 M HCl (10.9 mL, 19.6 mmol), and stirred at room temperature (rt) for 1.5 h. The reaction mixture was diluted with water (75 mL) and extracted with diethyl ether (3 x 75 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. Reconcentration from hexanes afforded the desired product (8.70 g, 99.8%) as an orange solid, which was used without further purification. C9H7BrF3O (M-CN) + LCMS for: m / z = 267.0, 269.0; Found: 266.9, 269.0.
[0203] Step 4. 2-(3-bromo-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide (second-eluting enantiomer) [ka] A solution of 2-(3-bromo-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanenitrile (8.70 g, 29.6 mmol) in 1,4-dioxane (59.2 mL) at 0° C. was treated with concentrated HCl (9.00 mL, 108 mmol) pre-cooled in an ice bath. HCl gas was bubbled through the reaction mixture while stirring at 0° C. for 45 min. The cooling bath was removed and the reaction mixture was stirred at room temperature for 61 h. Nitrogen was bubbled through the reaction mixture for 10 min to remove some of the HCl, cooled to 0° C., and diluted with brine (200 mL), water (50 mL), and ethyl acetate (200 mL). The organic layer was separated and the aqueous layer was diluted with water (100 mL) to dissolve the remaining solids. The aqueous layer was extracted with ethyl acetate (100 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated to give a brown oil. Purification by flash column chromatography using MTBE (0% to 60%) in hexanes afforded the racemic product as a yellow oily solid. The racemic mixture was separated by preparative chiral HPLC (Phenomenex Lux Amylose-1 [21.2 x 250 mm, 5 micrometer], eluting with 95% ethanol in hexanes at a flow rate of 18 mL / min, loaded approximately 100 mg in 2 mL of ethanol) to give the desired second eluting enantiomer (4.50 g, 48.8%) as a viscous yellow oil. The first enantiomer to elute had a retention time of 4.0 min. The second enantiomer to elute had a retention time of 5.3 min.
[0204] Second eluting enantiomer: 1 H NMR (400 MHz, DMSO-d6) δ 7.85 (d, J = 1.9 Hz, 1H), 7.75 (s, 1H), 7.67 (s, 1H), 7.63 - 7.53 (m, 2H), 7.41 (d, J = 8.1 Hz, 1H), 2.35 (s, 3H). C 10 H 10 BrF3NO2(M+H) + LCMS for: m / z = 312.0, 314.0; Found: 312.0, 314.0.
[0205] Step 5. 3,3,3-Trifluoro-2-hydroxy-2-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanamide [ka] A solution of 2-(3-bromo-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide (3.57 g, 11.5 mmol) (Example 1, step 4, second eluting enantiomer) in 1,4-dioxane (57.2 mL) was treated with bis(pinacolato)diboron (3.49 g, 13.7 mmol) and potassium acetate (3.71 g, 37.8 mmol) and degassed with nitrogen for 5 minutes. The reaction mixture was treated with bis(triphenylphosphine)palladium(II) chloride (0.482 g, 0.687 mmol), degassed for 5 minutes, and stirred at 100° C. for 2.5 hours. The reaction mixture was diluted with ethyl acetate (50 mL), filtered through Celite®, and rinsed with additional ethyl acetate (100 mL). The filtrate was washed with brine, dried over sodium sulfate, filtered, and concentrated to a brown foam. Purification by flash column chromatography using MTBE (0% to 100%) in hexanes gave the desired product (3.35 g, 81.5%) as a viscous yellow foam. 1 H NMR (400 MHz, DMSO-d6) δ 7.96 (d, J = 2.2 Hz, 1H), 7.63 (dd, J = 7.9, 2.1 Hz, 1H), 7.58 (s, 1H), 7.54 (s, 1H), 7.51 - 7.40 (m, 1H), 7.21 (d, J = 8.2 Hz, 1H), 2.46 (s, 3H), 1.30 (s, 12H). C 16 H 22 BF3NO4(M+H) + LCMS for: m / z = 360.2; Found: 360.1.
[0206] Step 6. 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide A solution of 3-bromo-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-8-amine (7.50 g, 26.7 mmol) and 3,3,3-trifluoro-2-hydroxy-2-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanamide (10.5 g, 29.4 mmol) (Example 1, step 5) in 1,4-dioxane (133 mL) was treated with 1.0 M potassium carbonate in water (53.4 mL, 53.4 mmol), degassed with nitrogen for 5 minutes, treated with dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (3.27 g, 4.00 mmol), degassed with nitrogen for an additional 5 minutes, and stirred at 100° C. for 19 hours. The reaction mixture was treated with ethyl acetate (200 mL) and brine (50 mL), filtered through Celite, and the Celite was rinsed with additional ethyl acetate. The aqueous layer was separated from the filtrate and extracted with ethyl acetate (200 mL). The combined organic extracts were dried over sodium sulfate, filtered, and concentrated to a brown foam. Purification by flash column chromatography using MeOH (0% to 10%) in dichloromethane gave the desired product as a red / brown foam that was not completely pure. This material was repurified by flash column chromatography using MeOH (0% to 15%) in dichloromethane to give the desired product as an orange / brown foam that was still not completely pure. This material was repurified by flash column chromatography using ethyl acetate (with 5% MeOH) in hexanes (0% to 100%) to give the desired product as a white foam that was still impure. This material was repurified by flash column chromatography using acetonitrile (containing 5% MeOH) in dichloromethane (0% to 100%) to give the desired product (4.67 g, 40.4%) as a white foam. 1H NMR (600 MHz, DMSO-d6) δ 7.79 (s, 1H), 7.76 - 7.71 (m, 2H), 7.71 - 7.64 (m, 4H), 7.61 (d, J = 3.5 Hz, 2H), 7.51 (d, J = 8.2 Hz, 1H), 2.23 (s, 3H). C 17 H 14 F6N5O2(M+H) + LCMS for: m / z = 434.1; Found: 434.1.
[0207] Example 2: Preparation and characterization of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IA (free base) A vial was charged with 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide (0.050 g, 0.115 mmol) and stirred at 80° C. while a 1:2 premixed solution of isopropyl acetate (0.676 mL) / heptane (1.34 mL) was added dropwise. After 2 mL was added, the solid did not completely dissolve and some remained at the bottom of the vial. After nearly all the solid had dissolved, new solid had formed on the walls of the vial. After stirring at 80° C. for 2 hours, more solid had formed. After cooling to ambient temperature, the solid was filtered and washed with heptane. The solid was collected and dried under vacuum for 30 minutes to give 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide (Form IA) (33.2 mg, 66.4%) as a white solid.
[0208] Form IA was confirmed as a crystalline solid by XRPD analysis. The XRPD pattern of Form IA is shown in Figure 1, and the peak data is provided in Table 1 below. [Table 1]
[0209] DSC analysis of form IA revealed one endothermic peak with an onset temperature of 191.9° C. and a maximum of 193.2° C. The DSC thermogram is shown in FIG.
[0210] TGA analysis of Form IA revealed significant weight loss above 200° C. due to decomposition of the sample. The TGA thermogram is shown in FIG.
[0211] Form IA was identified as an anhydrous, unsolvated crystalline form.
[0212] Example 3: Preparation and characterization of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IIA (free base) Approximately 100 mg of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide free base was dissolved in 1 mL of isopropyl acetate in a 4 mL clear glass vial. 2 mL of heptane was added to the solution with stirring at ambient temperature. The mixture was heated at 80° C. with stirring for 2 hours. The mixture was cooled to ambient temperature and stirred for 1 hour. The solid was collected by filtration and air-dried to provide 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide (Form IIA).
[0213] Form IIA was confirmed as a crystalline solid by XRPD analysis. The XRPD pattern of Form IIA is shown in Figure 4, and the peak data is shown in Table 2 below. [Table 2]
[0214] DSC analysis of Form IIA revealed one endothermic peak with an onset temperature of 177.2° C. and a maximum of 179.7° C. The DSC thermogram is shown in FIG.
[0215] TGA analysis of Form IIA revealed significant weight loss above 200° C. due to decomposition of the sample. The TGA thermogram is shown in FIG.
[0216] Form IIA was identified as an anhydrous, non-solvated crystalline form.
[0217] Example 4: Preparation and characterization of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline form IIIA (free base) Approximately 72 mg of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide free base was dissolved in 1 mL of MeOH in a 4 mL clear glass vial. The solution was evaporated to dryness at ambient temperature. The resulting solid, a MeOH solvate, was dried overnight under vacuum at 60° C. to give 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide (Form IIIA).
[0218] Form IIIA was confirmed as a crystalline solid by XRPD analysis. The XRPD pattern of Form IIIA is shown in Figure 7, and the peak data is shown in Table 3 below. [Table 3]
[0219] DSC analysis of Form IIIA revealed one endothermic peak with an onset temperature of 134.3° C. and a maximum of 143.0° C. The DSC thermogram is shown in FIG.
[0220] TGA analysis of Form IIIA revealed significant weight loss above 200° C. due to decomposition of the sample. The TGA thermogram is shown in FIG.
[0221] Form IIIA was identified as an anhydrous, non-solvated crystalline form.
[0222] Examples 5-6. 8-Amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide (Enantiomers 1 and 2) [ka] Step 1. 6,8-Dibromo-3-iodoimidazo[1,2-a]pyrazine [ka] To a solution of 6,8-dibromoimidazo[1,2-a]pyrazine (0.50 g, 1.8 mmol) [Combi-Blocks, OR-7964] in DMF (12 mL) was added N-iodosuccinimide (0.45 g, 2.0 mmol). The reaction mixture was then heated at 60° C. for 15.5 h. The reaction mixture was concentrated in vacuo. The resulting solid was taken up in dichloromethane (DCM). The organic layer was washed successively with water and saturated Na2S2O3 (aq). The organic layer was then dried over Na2SO4, filtered, and concentrated to give the title compound as a pale yellow solid (0.64 g, 88%). C6H3Br2IN3 (M+H) + LCMS for: calculated m / z = 401.8, 403.8, 405.8; found 401.8, 403.7, 405.6.
[0223] Step 2. 6-Bromo-3-iodo-N-(4-methoxybenzyl)imidazo[1,2-a]pyrazin-8-amine [ka] A solution of 6,8-dibromo-3-iodoimidazo[1,2-a]pyrazine (1.67 g, 3.57 mmol), N,N-diisopropylethylamine (1.24 mL, 7.13 mmol), and (4-methoxyphenyl)methanamine (0.512 mL, 3.92 mmol) in iPrOH (11.9 mL) was heated in a microwave at 110° C. for 1 h. After cooling to room temperature, the solidified reaction mixture was diluted with isopropanol (75 mL) and water (19 mL) and stirred for 10 min. The solid was collected by filtration to give the desired product (1.41 g, 86.1%), which was used without further purification. 14 H 13 BrIN4O (M+H) + LCMS for: calculated m / z = 458.9, 460.9; found 459.0, 461.0.
[0224] Step 3. 6-Bromo-3-iodoimidazo[1,2-a]pyrazine-8-amine trifluoroacetate [ka] A solution of 6-bromo-3-iodo-N-(4-methoxybenzyl)imidazo[1,2-a]pyrazin-8-amine (2.72 g, 5.92 mmol) in trifluoroacetic acid (TFA, 14.8 mL) was stirred at 55° C. for 5.5 h. The reaction mixture was concentrated, diluted with acetonitrile (2×), and then reconcentrated. The solid was diluted with ethyl acetate (12 mL) and stirred at room temperature for 1 h. The slurry was diluted with hexanes (12 mL) dropwise and stirred at room temperature for 75 min. The solid was collected by filtration to give the desired product (2.03 g, 75.7%), which was used without further purification. C6H5BrIN4(M+H) + LCMS for: calculated m / z = 338.9, 340.9; found 338.8, 340.8.
[0225] Step 4. 2-(3-bromo-4-methylphenyl)-1,1,1-trifluoropropan-2-ol [ka] A solution of 1-(3-bromo-4-methylphenyl)ethan-1-one (1.20 g, 5.63 mmol) [Aldrich, 579734] in tetrahydrofuran (22.5 mL) at 0° C. was treated with trimethyl(trifluoromethyl)silane (1.00 mL, 6.76 mmol) [Aldrich, 488712] and stirred at 0° C. for 5 min. The reaction mixture was treated with 1.0 M tetra-n-butylammonium fluoride in tetrahydrofuran (0.282 mL, 0.282 mmol) at 0° C. and stirred at room temperature for 1 h. The reaction mixture was cooled to 0° C. and treated with additional 1.0 M tetra-n-butylammonium fluoride in tetrahydrofuran (6.76 mL, 6.76 mmol) and stirred at room temperature for 30 min. The reaction mixture was diluted with ethyl acetate (100 mL) and washed with brine (2×75 mL). The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography using ethyl acetate in hexanes (0% to 30%) afforded the desired product (1.54 g, 96.7%) as a yellow oil. 10 H9BrF3(M-OH) + LCMS for: m / z = 265.0, 267.0; Found: 264.9, 267.0.
[0226] Step 5. 1,1,1-trifluoro-2-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-ol [ka] A mixture of 2-(3-bromo-4-methylphenyl)-1,1,1-trifluoropropan-2-ol (0.252 g, 0.890 mmol), bis(pinacolato)diboron (0.294 g, 1.16 mmol) and potassium acetate (0.288 g, 2.94 mmol) in tetrahydrofuran (4.95 mL) was degassed with nitrogen for 5 minutes. The reaction mixture was treated with triphenylphosphinepalladium chloride (0.025 g, 0.036 mmol), degassed with nitrogen for an additional 5 minutes and heated in a microwave at 135° C. for 20 minutes. The reaction mixture was diluted with ethyl acetate and filtered through a 0.5 micrometer cartridge, which was rinsed with ethyl acetate. The filtrate was washed with water and brine, dried over sodium sulfate, filtered and concentrated to give a crude residue. Purification by flash column chromatography using ether in hexanes (0% to 50%) afforded the desired product (272 mg, 92.5%) as a colorless oil. 16 H 23 BF3O3(M+H) + LCMS for: m / z = 331.2; Found: 331.2.
[0227] Step 6. 2-(3-(8-amino-6-bromoimidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-1,1,1-trifluoropropan-2-ol [ka] A mixture of 6-bromo-3-iodoimidazo[1,2-a]pyrazine-8-amine trifluoroacetate (step 3, 0.855 g, 1.89 mmol), 1,1,1-trifluoro-2-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-ol (step 5; 0.623 g, 1.89 mmol), and tetrakis(triphenylphosphine)palladium(0) (0.131 g, 0.113 mmol) in ethanol (12.6 ml) was treated with 2.0 M sodium carbonate in water (1.89 ml, 3.77 mmol), degassed with nitrogen for 5 minutes, and heated at 130° C. for 2 hours in a microwave reactor. The reaction mixture was partially concentrated to remove ethanol and diluted with ethyl acetate and water. The solids were removed by filtration and the aqueous layer of the filtrate was separated and extracted with ethyl acetate (2x). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated to give the crude residue. Purification by flash column chromatography using methanol (0% to 2%) in dichloromethane afforded the desired product (610 mg, 77.8%) as a white foam. 16 H 15 BrF3N4O (M+H) + LCMS for: m / z = 415.0, 417.0; Found: 415.0, 417.0.
[0228] Step 7. Methyl 8-amino-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxylate [ka] A solution of 2-(3-(8-amino-6-bromoimidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-1,1,1-trifluoropropan-2-ol (Step 6; 0.250 g, 0.602 mmol) in methanol (16.1 ml) was treated with triethylamine (0.336 ml, 2.41 mmol) and degassed with nitrogen for 5 min. The reaction mixture was treated with Pd(dppf)2CH2Cl2 (0.049 g, 0.060 mmol), degassed with nitrogen for a further 5 min, saturated with CO by bubbling the gas under the reaction surface for 3 min, and heated at 60 °C overnight. The reaction mixture was concentrated and the resulting red oil was diluted with ethyl acetate, water, and saturated sodium bicarbonate. The aqueous layer was separated and re-extracted with ethyl acetate (2x). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated to a brown oil. Purification by flash column chromatography using methanol (0% to 4%) in dichloromethane afforded the desired product (158 mg, 66.5%) as a tan oily solid. 18 H 18 F3N4O3(M+H) + LCMS for: m / z = 395.1; Found: 395.1.
[0229] Step 8. 8-Amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide A solution of methyl 8-amino-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxylate (Step 7, 0.080 g, 0.203 mmol) in THF (3.38 mL) was treated with 1-amino-2-methylpropan-2-ol (0.181 g, 2.03 mmol) followed by trimethylaluminum (0.507 mL, 1.01 mmol) (2M in toluene) and stirred at 80° C. overnight. The reaction mixture was treated with additional trimethylaluminum (0.70 ml, 1.40 mmol) (2M in toluene) and stirred at 80° C. overnight. The reaction mixture was cooled to room temperature, diluted with methanol, and filtered through a pad of Celite®. After rinsing with MeOH (2×), the filtrate was concentrated to a tan oil. Purification by silica gel chromatography (0-5% MeOH / DCM) afforded the title compound as an oily solid (26 mg, 28%), which was a mixture of enantiomers. The racemic mixture was separated by preparative chiral HPLC (Phenomenex Lux Amylose-1 [21.2 x 250 mm, 5 micrometer], eluting with 12% ethanol in hexane at a flow rate of 18 mL / min, loaded approximately 8 mg in 800 μL of ethanol). The first peak to elute had a retention time of 11.9 minutes (Example 1; Enantiomer 1). The second peak to elute had a retention time of 16.1 minutes (Example 2, Enantiomer 2).
[0230] Example 5 (Enantiomer 1): 1 H NMR (400 MHz, DMSO-d6) δ 8.08 (t, J = 6.1 Hz, 1H), 7.70 (d, J = 2.8 Hz, 2H), 7.65 (d, J = 8.1 Hz, 1H), 7.58 (s, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.36 (s, 2H), 6.65 (s, 1H), 4.65 (s, 1H), 3.22 (d, J = 6.1 Hz, 2H), 2.15 (s, 3H), 1.70 (s, 3H), 1.09 (s, 6H). C 21 H 25F3N5O3(M+H) + LCMS for: m / z = 452.2; Found: 452.1.
[0231] Example 6 (Enantiomer 2): 1 H NMR (600 MHz, DMSO-d6) δ 8.08 (t, J = 6.0 Hz, 1H), 7.70 (d, J = 3.0 Hz, 2H), 7.65 (d, J = 8.2 Hz, 1H), 7.58 (s, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.36 (s, 2H), 6.65 (s, 1H), 4.65 (s, 1H), 3.22 (d, J = 6.1 Hz, 2H), 2.15 (s, 3H), 1.70 (s, 3H), 1.09 (s, 6H). C 21 H 25 F3N5O3(M+H) + LCMS for: m / z = 452.2; Found: 452.2.
[0232] Example 7: Preparation and characterization of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, crystalline form IB (free base) A round bottom flask was charged with 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide (enantiomer 2 from Example 6, step 8; 184 g, 408 mmol) and isopropyl acetate (950 mL). The mixture was stirred at 80° C. for 1 h, cooled to room temperature (RT), and stirred at RT overnight. The solid was collected to give 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide (Form IB, 152 g, 82.8%).
[0233] Form IB was confirmed as a crystalline solid by XRPD analysis. The XRPD pattern of Form IB is shown in Figure 10 and the peak data is shown in Table 4 below. [Table 4]
[0234] DSC analysis of form IB revealed one endothermic peak with an onset temperature of 172.2° C. and a maximum at 174.2° C. The DSC thermogram is shown in Figure 11. Form IB was confirmed to be an anhydrous, unsolvated crystalline form.
[0235] Example 8: Preparation and characterization of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, crystalline form IIB (free base) A vial was charged with 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide (enantiomer 2 from Example 6, step 8; 252 mg, 0.559 mmol) and isopropyl acetate (1.25 mL) and the solids were allowed to slowly dissolve. The mixture was treated with heptane (0.35 mL) until solids persisted. The mixture was heated at 80° C. for 30 min and stirred at RT overnight. The solid was collected to give 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide (Form IIB, 116 mg, 46.0%).
[0236] Form IIB was confirmed as a crystalline solid by XRPD analysis. The XRPD pattern of Form IIB is shown in Figure 12, and the peak data is shown in Table 5 below. [Table 5]
[0237] DSC analysis of Form IIB revealed one endothermic peak with an onset temperature of 161.7° C. and a maximum at 165.4° C. The DSC thermogram is shown in Figure 8. Form IIB was confirmed to be an anhydrous, nonsolvated crystalline form.
[0238] Example 9. 8-Amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide [ka] Step 1. 1-(4-(methyl-d3)phenyl)ethan-1-one [ka] A solution of (4-acetylphenyl)boronic acid (1.00 g, 6.10 mmol) [Aldrich, 470821], bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (0.108 g, 0.152 mmol), and cesium fluoride (3.24 g, 21.4 mmol) in DMF (10.2 mL) and water (2.03 mL) was degassed with nitrogen for 10 min, treated with iodomethane-d3 (1.44 mL, 23.2 mmol), and stirred at 45° C. overnight. The reaction mixture was cooled to rt and diluted with water and ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate (2×). The combined organic extracts were washed with water and brine, dried over magnesium sulfate, filtered and concentrated (60-70 Torr, 25° C. bath) to give the desired product (546 mg, 65.3%) as a yellow oil which was used without further purification. 1 H NMR (400 MHz, CDCl3) δ 7.86 (d, J= 8.0 Hz, 2H), 7.26 (d, J= 8.0 Hz, 2H), 2.58 (s, 3H). C9H8D3O (M+H) + LCMS for: m / z = 138.1; Found: 138.1.
[0239] Step 2. 1-(3-bromo-4-(methyl-d3)phenyl)ethan-1-one [ka] A suspension of aluminum chloride (13.6 g, 102 mmol) in dichloromethane (24 mL) was treated with 1-(4-(methyl-d3)phenyl)ethan-1-one (6.35 g, 46.3 mmol) dropwise via syringe over 5 min. The remaining material in the syringe was rinsed with dichloromethane (7.0 mL) and added dropwise to the reaction mixture. After the initial exotherm, the reaction mixture was cooled to rt for 3 min, stirred at 35° C. for 5 min, and treated with bromine (2.38 mL, 46.3 mmol) dropwise over 5 min. The reaction mixture was stirred for 25 min before being slowly added to a mixture of dichloromethane (50 mL), 1N HCl (100 mL), and ice. The remaining reaction mixture was rinsed into the dichloromethane / HCl / ice mixture with additional dichloromethane. The mixture was warmed to room temperature (rt) and the layers were separated. The aqueous layer was extracted with dichloromethane (2×75 mL). The combined organic layers were washed with saturated sodium bicarbonate and brine. The sodium bicarbonate and brine washes contained the product and were combined, acidified with 1 M HCl and extracted with dichloromethane (2×50 mL). All the organic layers were combined, dried over magnesium sulfate, filtered and concentrated to a yellow oil. Purification by flash column chromatography using ethyl acetate in hexanes (0% to 15%) afforded the desired product (9.08 g, 90.8%) as a pale yellow solid. 1 H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 1.8 Hz, 1H), 7.79 (dd, J = 7.9, 1.8 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 2.57 (s, 3H). C9H7D3BrO (M+H) + LCMS for: m / z = 216.0, 218.0; Found: 216.0, 218.0.
[0240] Step 3. 2-(3-bromo-4-(methyl-d3)phenyl)-1,1,1-trifluoropropan-2-ol [ka] A solution of 1-(3-bromo-4-(methyl-d3)phenyl)ethan-1-one (9.08 g, 42.0 mmol) in tetrahydrofuran (168 mL) at 0° C. was treated with trimethyl(trifluoromethyl)silane (8.07 mL, 58.8 mmol) [Aldrich, 488712] and stirred at 0° C. for 5 min. The reaction mixture was treated with 1.0 M tetra-n-butylammonium fluoride in tetrahydrofuran (2.10 mL, 2.10 mmol) at 0° C. and stirred at room temperature for 1 h. The reaction mixture was treated with 1.0 M tetra-n-butylammonium fluoride in tetrahydrofuran (12.6 mL, 12.6 mmol) and water (9.8 mL) and stirred at room temperature for 30 min. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography using ethyl acetate in hexanes (0% to 20%) afforded the desired product (13.3 g, 111%) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ 7.79 - 7.72 (m, 1H), 7.48 - 7.35 (m, 1H), 7.24 (s, 1H), 2.41 (br s, 1H), 1.76 (s, 3H).
[0241] Step 4. 1,1,1-trifluoro-2-(4-(methyl-d3)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-ol [ka] A suspension of bis(pinacolato)diboron (12.8 g, 50.2 mmol) and potassium acetate (8.63 mL, 138 mmol) in dioxane (24 mL) was treated with 2-(3-bromo-4-(methyl-d3)phenyl)-1,1,1-trifluoropropan-2-ol (13.3 g, 41.8 mmol). The remaining 2-(3-bromo-4-(methyl-d3)phenyl)-1,1,1-trifluoropropan-2-ol was rinsed with dioxane (106 mL) and added to the reaction mixture, which was degassed with nitrogen for 10 minutes. The reaction mixture was treated with bis(triphenylphosphine)palladium(II) dichloride (1.16 g, 1.67 mmol), degassed with nitrogen for an additional 10 minutes, and stirred at 100° C. overnight. The reaction mixture was cooled to rt, degassed with nitrogen for 5 min, treated with additional bis(triphenylphosphine)palladium(II) dichloride (1.16 g, 1.67 mmol), degassed with nitrogen for another 5 min, and stirred at 100° C. for 4 h. The reaction mixture was filtered through Celite® and rinsed with THF and ethyl acetate. The filtrate was washed with 1:1 water / brine (300 mL). The aqueous layer was re-extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to a brown oil. Purification by flash column chromatography using MTBE (0%-20%) in hexanes afforded the desired product (14.4 g, 84.7%) as a pale yellow oil. 1 H NMR (400 MHz,CDCl3) δ 7.93 (d, J = 2.3 Hz, 1H), 7.55 - 7.45 (m, 1H), 7.19 (d, J = 8.1 Hz, 1H), 2.43 (br s, 1H), 1.77 (s, 3H), 1.34 (s, 12H). C 16 H 20 D3BF3O3(M+H) + LCMS for: m / z = 334.2; Found: 334.3.
[0242] Step 5. 2-(3-(8-amino-6-bromoimidazo[1,2-a]pyrazin-3-yl)-4-(methyl-d3)phenyl)-1,1,1-trifluoropropan-2-ol (racemic mixture) [ka] A solution of 1,1,1-trifluoro-2-(4-(methyl-d3)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-ol (14.5 g, 35.6 mmol) in dioxane (178 mL) was treated with 6-bromo-3-iodoimidazo[1,2-a]pyrazin-8-amine (12.1 g, 35.6 mmol), degassed with nitrogen for 5 minutes, treated with dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (5.81 g, 7.11 mmol) and degassed with nitrogen for an additional 5 minutes. The reaction mixture was treated with 1.0 M potassium carbonate in water (107 ml, 107 mmol), degassed with nitrogen for 5 minutes and stirred at 80° C. overnight. The reaction mixture was cooled to rt and filtered through Celite®. The Celite® was rinsed with ethyl acetate and water. The filtrate was diluted with water (150 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to a dark oil. Purification by flash column chromatography using methanol (0%-5%) in dichloromethane and repurification by flash column chromatography using ethyl acetate (0%-100%) in hexanes gave the desired product (13.8 g, 92.8%). C 16 H 12 D3BrF3NO (M+H) + LCMS for: m / z = 418.1, 420.1; Found: 418.0, 420.0.
[0243] Step 6. Second eluting enantiomer of 2-(3-(8-amino-6-bromoimidazo[1,2-a]pyrazin-3-yl)-4-(methyl-d3)phenyl)-1,1,1-trifluoropropan-2-ol [ka] A racemic mixture of 2-(3-(8-amino-6-bromoimidazo[1,2-a]pyrazin-3-yl)-4-(methyl-d3)phenyl)-1,1,1-trifluoropropan-2-ol was separated by preparative chiral HPLC (Phenomenex Lux Amylose-1 [21.2 x 250 mm, 5 micrometer], eluting with 20% ethanol in hexanes at a flow rate of 20 mL / min, loading approximately 200 mg in 4 mL ethanol). The first peak to elute had a retention time of 9.6 minutes. The second peak to elute had a retention time of 14.6 minutes.
[0244] Peak 2: 1 H NMR (400 MHz, DMSO-d6) δ 7.66 - 7.59 (m, 2H), 7.59 - 7.53 (m, 3H), 7.46 (d, J = 8.1 Hz, 1H), 7.25 (s, 1H), 6.66 (s, 1H), 1.71 (s, 3H). LCMS for C16H12D3BrF3N4O (M+H)+: m / z = 418.1, 420.1; found: 418.0, 420.0.
[0245] Step 7. Methyl 8-amino-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxylate (single enantiomer prepared) [ka] A solution of 2-(3-(8-amino-6-bromoimidazo[1,2-a]pyrazin-3-yl)-4-(methyl-d3)phenyl)-1,1,1-trifluoropropan-2-ol (peak 2 from step 6, 4.95 g, 48.9 mmol) in methanol (163 mL) and DMF (40.7 mL) was treated with triethylamine (6.81 mL, 48.9 mmol) and degassed with nitrogen for 5 min. The reaction mixture was treated with Pd(dppf)2CH2Cl2 (0.998 g, 1.22 mmol), degassed with nitrogen for an additional 5 min, saturated with CO by bubbling the gas under the reaction surface for 3 min, and heated at 60 °C overnight. The reaction mixture was concentrated and the resulting oil was diluted with ethyl acetate and water. The aqueous layer was separated and re-extracted with ethyl acetate (3x). The combined organic layers were washed with water, saturated ammonium chloride solution, and brine, dried over magnesium sulfate, filtered, and concentrated to a brown oil. Purification by flash column chromatography using methanol (0% to 5%) in dichloromethane afforded the desired product (4.49 g, 92.4%) as an orange solid. 18 H 15 D3F3N4O3(M+H) + LCMS for: m / z = 398.1; Found: 398.3.
[0246] Step 8. 8-Amino-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxylic acid (single enantiomer prepared) [ka] A solution of methyl 8-amino-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxylate (4.49 g, 11.3 mmol) (single enantiomer from step 7) in methanol (113 mL) was treated with 1.0 M sodium hydroxide (56.5 mL, 56.5 mmol) and stirred at room temperature. The reaction mixture was concentrated to remove methanol, diluted with water (50 mL) and extracted with ethyl acetate (50 mL, then 20 mL). The combined ethyl acetate layers were extracted with additional 1.0 M sodium hydroxide (3×20 mL). The combined basic aqueous layers were adjusted to pH ∼5 with citric acid (7.6 g). The aqueous layer was extracted with dichloromethane (2×150 mL). The aqueous layer was diluted with brine and extracted with ethyl acetate (150 mL). The combined organic layers were concentrated to give the desired product (4.06 g, 93.8%) as a tan solid which was used without further purification. 1 H NMR (400 MHz, DMSO-d6) δ 7.76 (s, 1H), 7.71 (s, 1H), 7.65 (dd, J = 8.2, 2.0 Hz, 1H), 7.59 (d, J = 2.0 Hz, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.30 (br s, 2H), 6.66 (s, 1H), 1.71 (s, 3H). C 17 H 13 D3F3N4O3(M+H) + LCMS for: m / z = 384.1; Found: 384.2.
[0247] Step 9. 8-Amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide A solution of 8-amino-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxylic acid (4.06 g, 10.6 mmol) (single enantiomer from step 8) in DMF (106 mL) was treated with 1-amino-2-methylpropan-2-ol (1.44 g, 16.2 mmol) [Ark Pharm, AK-37803] and HATU (6.16 g, 16.2 mmol), stirred for 15 min, treated with triethylamine (4.43 mL, 31.8 mmol) and stirred at room temperature for 3.5 h. The reaction mixture was diluted with water (500 mL) and brine (100 mL) and extracted with ethyl acetate (3×150 mL). The combined organics were washed with saturated ammonium chloride (150 mL), 11% sodium carbonate (150 mL), and brine (100 mL), dried over magnesium sulfate, filtered, and concentrated to a tan oil. Purification by flash column chromatography using methanol (0% to 5%) in dichloromethane afforded the desired product (4.28 g, 89.0%) as a foam. 1 H NMR (600 MHz, DMSO-d6) δ 8.14 - 8.05 (m, 1H), 7.74 - 7.69 (m, 2H), 7.66 (d, J = 7.9 Hz, 1H), 7.62 - 7.54 (m, 1H), 7.50 (dd, J = 8.2, 2.0 Hz, 1H), 7.38 (s, 2H), 6.67 (s, 1H), 4.67 (s, 1H), 3.23 (d, J = 5.6 Hz, 2H), 1.71 (s, 3H), 1.10 (s, 6H). C 21 H 22 LCMS for D3F3N5O3(M+H)+: m / z = 455.2; Found: 455.2.
[0248] Example 10: Preparation and characterization of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, crystalline form IC (free base) A round bottom was charged with 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide (4.60 g, 10.1 mmol) and isopropyl acetate (25.5 mL) and heated at 80° C. The mixture was stirred at 80° C. and within 5 min a solid began to form. The mixture was stirred at 80° C. for 1 h. Heating was discontinued and the mixture was stirred for 1 h while cooling to rt. The mixture was treated with heptane (25.5 mL) dropwise from an addition funnel over 35 min and stirred at room temperature for 40 min. The solid was collected, washed with 1:1 isopropyl acetate / heptane (10 mL) and dried under reduced pressure at 60° C. for 24 hours to give 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide (Form I) (4.16 g, 90.4%).
[0249] Form IC was confirmed as a crystalline solid by XRPD analysis. The XRPD pattern of Form IC is shown in Figure 14 and the peak data is shown in Table 6 below. [Table 6]
[0250] DSC analysis of Form IC revealed one endothermic peak with an onset temperature of 173.4° C. and a maximum at 179.0° C. The DSC thermogram is shown in Figure 15. Form IC was confirmed to be an anhydrous, nonsolvated crystalline form.
[0251] Example 11. 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide (HBr) salt 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide free base (98.81 mg) was dissolved in 2.5 mL of methanol in a 4 mL clear glass vial. 42.4 μL of 6 M aqueous HBr solution (1.2 equiv.) was added to the solution and mixed thoroughly. The solution was allowed to evaporate at room temperature to give HBr salt crystals.
[0252] Example 12. Characterization of single crystal 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide (HBr) salt Crystal Data: C35H32Br2F12N10O5, from methanol, colorless, irregular plate, ca. 0.450 x 0.210 x 0.060 mm, monoclinic, C2, a = 20.055(7) Å, b = 10.115(4) Å, c = 21.363(8) Å, beta = 94.953(7), volume = 4318(3) Å 3 , Z=4, T=-40℃, formula weight=1060.52, density=1.631g / cm 3 , μ(Mo)=1.98mm -1 .
[0253] Data Collection: Data collection was performed using a Bruker SMART APEX-II CCD system, MoK alpha radiation, standard focus tube, anode power = 50 kV x 30 mA, crystal to plate distance = 5.0 cm, 512 x 512 pixels / frame, beam center = (259.19, 253.13), total frames = 2635, oscillations / frame = 0.50°, exposure / frame = 40.1 sec / frame, SAINT integration, hkl min / max = (-26, 26, -12, 13, -27, 27), data input to shelx = 38968, unique data = 9756, 2theta range = 4.51 to 55.43°, completeness for 2theta 55.43 = 99.60%, R(int-xl) = 0.0672, SADABS correction applied.
[0254] Analysis and refinement: The crystal structure was analyzed using XS (Shelxtl) and refined using the shelxtl software package. 2 Full matrix least squares fit for, Scattering coefficients from Int.Tab.Vol C Tables 4.2.6.8 and 6.1.1.4, Number of data = 9756, Number of constraints = 1, Number of parameters = 584, Data / parameter ratio = 16.71, Goodness of fit for F2 = 1.14, R-index [I>4 sigma (I)] R1 = 0.0648, wR2 = 0.1560, R-index (all data) R1 = 0.1004, wR2 = 0.1719, Maximum difference of peaks and holes = 1.795 and -0.642 e / Å 3 The refinement was performed with a flack parameter = 0.038 (6). All hydrogen atoms were idealized using the riding model. Table 7 shows the atomic coordinates (×10 4 ) and equivalent isotropic displacement parameter (Å 2 ×10 3 ) is shown. U(eq) is defined as one third of the locus of the orthogonal Uij tensor. Table 8 shows the bond lengths [Å] and angles [deg]. Table 9 shows the anisotropic displacement parameters (Å 2 ×10 3 ) is shown.
[0255] Results: This analysis confirmed the structure of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide. The asymmetric unit contains two molecules of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, two bromides for charge balance, and one methanol solvent molecule, as shown in Figures 16A-16B. The enantiomer assignment was based on Flack parameters refined to 0.038(6). This study determined the absolute configuration of the chiral centers C15=S- and C35=S-. [Table 7-1] [Table 7-2] [Table 8-1] [Table 8-2] [Table 8-3] [Table 8-4] [Table 9-1] [Table 9-2]
[0256] Example A. THP-1 RPS6 ELISA Assay To measure phosphorylated ribosomal protein S6 (RPS6) in cell lysates, THP-1 cells (human acute monocytic leukemia) are purchased from ATCC (Manassas, VA) and maintained in RPMI containing 10% FBS (Gibco / Life Technologies, Carlsbad, CA). For the assay, THP-1 cells are serum starved overnight in RPMI and then incubated with 2×10 cells in 90 μL in RPMI in the presence or absence of a range of test compounds. 5Cells are plated at 1000 x 1000 cells / well into 96-well flat-bottom tissue culture treated plates (Corning, Corning, NY). Covered plates are incubated at 37°C, 5% CO2 for 2 hours and then treated with or without 10 nM MCP-1 (MYBioSource, San Diego, CA) for 15 minutes at 37°C, 5% CO2. Plates are centrifuged at 1600 RPM and the supernatant is removed. Cells are lysed for 30 minutes on wet ice in lysis buffer (Cell Signaling, Danvers, MA) containing protease inhibitors (Calbiochem / EMD, Germany), PMSF (Sigma, St Louis MO), HALTS (Thermo Fisher, Rockford, IL). Cell lysates are frozen at -80°C prior to testing. Lysates are tested in a human / mouse / rat Phospho-RPS6 ELISA (R&D Systems, Inc. Minn, MN). The plate is read using a microplate reader (SpectraMax M5 - Molecular Devices, LLC Sunnyvale, CA) set at 450 nm with wavelength compensation at 540. 50 is determined by curve fitting of percent inhibition of inhibitor versus the logarithm of inhibitor concentration using GraphPad Prism 5.0 software.
[0257] Example B. Scintillation Proximity Assay of PI3K-γ material [γ- 33[P]ATP (10 mCi / mL) and wheat germ agglutinin (WGA) YSi SPA scintillation beads were purchased from Perkin-Elmer (Waltham, MA). The lipid kinase substrate, D-myo-phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) D(+)-sn-1,2-di-O-octanoylglyceryl, 3-O-phospho-linked (PIP2), CAS 204858-53-7, was purchased from Echelon Biosciences (Salt Lake City, UT). PI3Kγ (p110γ) recombinant human protein was purchased from Life technologies (Grand Island, NY). ATP, MgCl2, DTT, EDTA, MOPS, and CHAPS were purchased from SigmaAldrich (St. Louis, MO).
[0258] Kinase reactions were performed in a final volume of 25 μL in polystyrene 384-well Greiner Bio-one white plates (Thermo Fisher Scientific). Inhibitors were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 2%. PI3Kγ assays were performed at room temperature in 20 mM MOPS (pH 6.7), 10 mM MgCl2, 5 mM DTT, and CHAPS 0.03%. Reactions were initiated by the addition of ATP, and the final reaction mixture contained 20 μM PIP2, 2 μM ATP, 0.5 μCi of [γ- 33 The reaction consisted of 10 nM PI3Kγ, 1 nM PO4, 1 nM β-P]ATP, and 13 nM PI3Kγ. Reactions were incubated for 120 min and terminated by the addition of 40 μL of SPA beads suspended in a stop buffer of 163 mM potassium phosphate (pH 7.8), 20% glycerol, and 25 mM EDTA. The final concentration of SPA beads was 1.0 mg / mL. After sealing the plates, they were shaken overnight at room temperature, centrifuged at 1500 rpm for 10 min, and the radioactivity of the products was determined by scintillation counting on a Topcount (Perkin-Elmer). IC 50Determination of the activity was performed by curve fitting of percent of solvent control activity versus the logarithm of inhibitor concentration using GraphPad Prism 6.0 software.
[0259] Example C. Scintillation Proximity Assay of PI3Kδ material [γ- 33 [P]ATP (10 mCi / mL) and wheat germ agglutinin (WGA) YSi SPA scintillation beads were purchased from Perkin-Elmer (Waltham, MA). The lipid kinase substrate, D-myo-phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) D(+)-sn-1,2-di-O-octanoylglyceryl, 3-O-phospho-linked (PIP2), CAS 204858-53-7, was purchased from Echelon Biosciences (Salt Lake City, UT). PI3Kδ (p110δ / p85α) recombinant human protein was purchased from Eurofins (St Charles, MO). ATP, MgCl2, DTT, EDTA, MOPS, and CHAPS were purchased from SigmaAldrich (St. Louis, MO).
[0260] Kinase reactions were performed in a final volume of 25 μL in polystyrene 384-well Greiner Bio-one white plates (Thermo Fisher Scientific). Inhibitors were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 2%. PI3Kδ assays were performed at room temperature in 20 mM MOPS (pH 6.7), 10 mM MgCl2, 5 mM DTT, and CHAPS 0.03%. Reactions were initiated by the addition of ATP, and the final reaction mixture contained 20 μM PIP2, 2 μM ATP, 0.5 μCi of [γ- 33Reactions consisted of 3.4 nM PI3Kδ, 1.0 nM 5H ATP, and 3.4 nM PI3Kδ. Reactions were incubated for 120 min and terminated by the addition of 40 μL of SPA beads suspended in a stop buffer of 163 mM potassium phosphate (pH 7.8), 20% glycerol, and 25 mM EDTA. The final concentration of SPA beads was 1.0 mg / mL. After sealing the plates, they were shaken overnight at room temperature, centrifuged at 1500 rpm for 10 min, and the radioactivity of the products was determined by scintillation counting on a Topcount (PerkinElmer). IC 50 Determination of the activity was performed by curve fitting of percent of solvent control activity versus the logarithm of inhibitor concentration using GraphPad Prism 6.0 software.
[0261] The compounds of Examples 1, 5, 6 and 9 were tested in the assays described in Examples A, B, and C and had IC values as shown in Table A below. 50 It has been found to have value. [Table 10] + IC ≤ 100 nM 50 ++ indicates IC ≤ 500 nM 50 +++ indicates IC<2000nM 50 ++++ indicates IC ≥ 2000 nM 50 Refers to... # indicates IC ≤ 100 nM 50 ## indicates IC ≤ 500nM 50 and ### indicates IC<1000nM 50 #### indicates IC ≥ 1000nM 50 Refers to...
[0262] In addition to those described herein, various modifications of the present invention will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application, including all patents, patent applications, and publications, is hereby incorporated by reference in its entirety. The present application also includes the following aspects. [Aspect 1] A crystalline form of the compound 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide. [Aspect 2] The crystalline form according to embodiment 1, which is anhydrous and unsolvated. [Aspect 3] The crystalline form according to embodiment 1 or 2, which is form IA. [Aspect 4] The crystalline form of any one of the preceding aspects, having an X-ray powder diffraction pattern comprising at least one peak at 8.6°±0.2° in terms of 2θ. [Aspect 5] The crystalline form of any one of the preceding embodiments, having an X-ray powder diffraction pattern comprising at least one peak at 9.5°±0.2° in terms of 2θ. [Aspect 6] and 14.9°±0.2°, wherein the crystalline form is a crystalline form having an X-ray powder diffraction pattern comprising the following peaks at 2θ: 8.6°±0.2°; 9.5°±0.2°; 10.3°±0.2°; 13.0°±0.2°; 13.6°±0.2°; 14.2°±0.2°; and 14.9°±0.2°, [Aspect 7] and 28.7°±0.2°, wherein the crystalline form is any one of embodiments 1 to 6, having an X-ray powder diffraction pattern comprising four or more of the following peaks at 2θ: 8.6°±0.2°; 9.5°±0.2°; 10.3°±0.2°; 13.0°±0.2°; 13.6°±0.2°; 14.2°±0.2°; 14.9°±0.2°; 17.3°±0.2°; 19.2°±0.2°; 20.6°±0.2°; 24.0°±0.2°; and 28.7°±0.2°. [Aspect 8] 8. The crystalline form of any one of embodiments 1 to 7, having an X-ray powder diffraction pattern substantially as shown in FIG. [Aspect 9] The crystalline form of any one of the preceding embodiments, having a DSC thermogram comprising an endothermic peak having a maximum at about 193° C. [Aspect 10] The crystalline form of any one of embodiments 1 to 9, having a differential scanning calorimetry thermogram (DSC) substantially as shown in FIG. 2. [Aspect 11] 11. The crystalline form of any one of embodiments 1 to 10, having a thermogravimetric analysis (TGA) substantially as shown in FIG. 3. [Aspect 12] The crystalline form according to embodiment 1 or 2, which is Form IIA. [Aspect 13] 13. The crystalline form of any one of embodiments 1, 2, and 12, having an X-ray powder diffraction pattern comprising at least one peak at 9.1°±0.2° in terms of 2θ. [Aspect 14] 14. The crystalline form of any one of embodiments 1, 2, 12, and 13, having an X-ray powder diffraction pattern comprising at least one peak at 11.1°±0.2° in terms of 2θ. [Aspect 15] 15. The crystalline form of any one of embodiments 1, 2, and 12-14, having an X-ray powder diffraction pattern comprising at least one peak at 12.6°±0.2° in terms of 2θ. [Aspect 16] 16. The crystalline form of any one of embodiments 1, 2, and 12-15, having an X-ray powder diffraction pattern comprising at least one peak at 13.5°±0.2° in terms of 2θ. [Aspect 17] 17. The crystalline form of any one of embodiments 1, 2, and 12-16, having an X-ray powder diffraction pattern comprising the following peaks at 2θ: 9.1°±0.2°; 11.1°±0.2°; 12.6°±0.2°; and 13.5°±0.2°. [Aspect 18] 18. The crystalline form of any one of embodiments 1, 2, and 12-17, having an X-ray powder diffraction pattern comprising four or more of the following peaks at 2θ: 9.1°±0.2°; 11.1°±0.2°; 12.6°±0.2°; 13.5°±0.2°; 18.0°±0.2°; 19.0°±0.2°; 20.5°±0.2°; and 21.9°±0.2°. [Aspect 19] 19. The crystalline form of any one of embodiments 1, 2, and 12-18, having an X-ray powder diffraction pattern substantially as shown in FIG. [Aspect 20] 20. The crystalline form of any one of embodiments 1, 2, and 12-19, having a DSC thermogram comprising an endothermic peak having a maximum at about 180° C. [Aspect 21] The crystalline form of any one of embodiments 1, 2, and 12 to 20, having a differential scanning calorimetry thermogram (DSC) substantially as shown in FIG. 5. [Aspect 22] The crystalline form of any one of embodiments 1, 2, and 12 to 21, having a thermogravimetric analysis (TGA) substantially as shown in FIG. [Aspect 23] The crystalline form according to embodiment 1 or 2, which is Form IIIA. [Aspect 24] 24. The crystalline form of any one of embodiments 1, 2, and 23, having an X-ray powder diffraction pattern comprising at least one peak at 8.1°±0.2° in terms of 2θ. [Aspect 25] 25. The crystalline form of any one of embodiments 1, 2, 23, and 24, having an X-ray powder diffraction pattern comprising at least one peak at 10.6°±0.2° in terms of 2θ. [Aspect 26] 26. The crystalline form of any one of embodiments 1, 2, and 23-25, having an X-ray powder diffraction pattern comprising at least one peak at 13.5°±0.2° in terms of 2θ. [Aspect 27] 27. The crystalline form of any one of embodiments 1, 2, and 23-26, having an X-ray powder diffraction pattern comprising the following peaks at 2θ: 8.1°±0.2°; 10.6°±0.2°; 13.5°±0.2°; and 14.2°±0.2°. [Aspect 28] 28. The crystalline form of any one of embodiments 1, 2, and 23-27, having an X-ray powder diffraction pattern comprising four or more of the following peaks in 2θ: 8.1°±0.2°; 10.6°±0.2°; 13.5°±0.2°; 14.2°±0.2°; 16.4°±0.2°; 17.1°±0.2°; 17.9°±0.2°; 20.3°±0.2°; and 24.1°±0.2°. [Aspect 29] 29. The crystalline form of any one of embodiments 1, 2, and 23-28, having an X-ray powder diffraction pattern substantially as shown in FIG. [Aspect 30] 30. The crystalline form of any one of embodiments 1, 2, and 23-29, having a DSC thermogram comprising an endothermic peak having a maximum at about 143° C. [Aspect 31] The crystalline form of any one of embodiments 1, 2, and 23-30, having a differential scanning calorimetry thermogram (DSC) substantially as shown in FIG. 8. [Aspect 32] The crystalline form of any one of embodiments 1, 2, and 23-31, having a thermogravimetric analysis (TGA) substantially as shown in FIG. 9. [Aspect 33] Crystalline form of the compound 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide. [Aspect 34] 34. The crystalline form according to embodiment 33, which is anhydrous and unsolvated. [Aspect 35] The crystalline form according to embodiment 33 or 34, which is form IB. [Aspect 36] 36. The crystalline form of any one of embodiments 33 to 35, having an X-ray powder diffraction pattern comprising at least one peak at 6.2°±0.2° in terms of 2θ. [Aspect 37] 37. The crystalline form of any one of embodiments 33 to 36, having an X-ray powder diffraction pattern comprising at least one peak at 15.6°±0.2° in terms of 2θ. [Aspect 38] 38. A crystalline form according to any one of embodiments 33 to 37, having an X-ray powder diffraction pattern comprising the following peaks at 2θ: 6.2°±0.2°; 10.4°±0.2°; 11.4°±0.2°; 11.6°±0.2°; 12.0°±0.2°; 13.9°±0.2°; 14.4°±0.2°; 15.6°±0.2°; 16.7°±0.2°; 20.7°±0.2°; and 23.2°±0.2°. [Aspect 39] 38. A crystalline form according to any one of embodiments 33 to 37, having an X-ray powder diffraction pattern comprising four or more of the following peaks at 2θ: 6.2°±0.2°; 10.4°±0.2°; 11.4°±0.2°; 11.6°±0.2°; 12.0°±0.2°; 13.9°±0.2°; 14.4°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; 20.7°±0.2°; and 23.2°±0.2°. [Aspect 40] 40. The crystalline form of any one of embodiments 33 to 39, having an X-ray powder diffraction pattern substantially as shown in FIG. 10. [Aspect 41] The crystalline form of any one of embodiments 33 to 40, having a DSC thermogram comprising an endothermic peak having a maximum at about 174° C. [Aspect 42] The crystalline form of any one of embodiments 33 to 41, having a differential scanning calorimetry thermogram (DSC) substantially as shown in FIG. 11. [Aspect 43] The crystalline form according to embodiment 33 or 34, which is form IIB. [Aspect 44] The crystalline form of any one of embodiments 33, 34, and 43, having an X-ray powder diffraction pattern comprising at least one peak at 4.2°±0.2° in terms of 2θ. [Aspect 45] The crystalline form of any one of embodiments 33, 34, 43, and 44, having an X-ray powder diffraction pattern comprising at least one peak at 13.3°±0.2° in terms of 2θ. [Aspect 46] The crystalline form of any one of embodiments 33, 34, and 43-45, having an X-ray powder diffraction pattern comprising at least one peak at 17.0°±0.2° in terms of 2θ. [Aspect 47] The crystalline form of any one of embodiments 33, 34, and 43-46, having an X-ray powder diffraction pattern comprising at least one peak at 18.8°±0.2° in terms of 2θ. [Aspect 48] 48. The crystalline form of any one of embodiments 33, 34, and 43-47, having an X-ray powder diffraction pattern comprising the following peaks at 2θ: 4.3°±0.2°; 7.4°±0.2°; 13.3°±0.2°; and 15.3°±0.2°. [Aspect 49] and 20.1°±0.2°, wherein the crystalline form is any one of embodiments 33, 34, and 43-47, having an X-ray powder diffraction pattern comprising four or more of the following peaks in 2θ: 4.3°±0.2°; 7.4°±0.2°; 13.3°±0.2°; 15.3°±0.2°; 15.5°±0.2°; 17.0°±0.2°; 17.2°±0.2°; 18.8°±0.2°; and 20.1°±0.2°. [Aspect 50] The crystalline form of any one of embodiments 33, 34, and 43-49, having an X-ray powder diffraction pattern substantially as shown in FIG. 12. [Aspect 51] The crystalline form of any one of embodiments 33, 34, and 43-50, having a DSC thermogram comprising an endothermic peak having a maximum at about 165° C. [Aspect 52] The crystalline form of any one of embodiments 33, 34, and 43-50, having a differential scanning calorimetry thermogram (DSC) substantially as shown in FIG. 13. [Aspect 53] The compound 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-d 3 )-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide crystalline form. [Aspect 54] 54. The crystalline form according to embodiment 53, which is anhydrous and unsolvated. [Aspect 55] 55. The crystalline form according to embodiment 53 or 54, which is form IC. [Aspect 56] 56. The crystalline form of any one of embodiments 53 to 55, having an X-ray powder diffraction pattern comprising at least one peak at 6.2°±0.2° in terms of 2θ. [Aspect 57] 57. The crystalline form of any one of embodiments 53 to 56, having an X-ray powder diffraction pattern comprising at least one peak at 11.9°±0.2° in terms of 2θ. [Aspect 58] 58. A crystalline form according to any one of embodiments 53 to 57, having an X-ray powder diffraction pattern comprising the following peaks at 2θ: 6.2°±0.2°; 10.4°±0.2°; 11.3°±0.2°; 11.9°±0.2°; and 12.5°±0.2°. [Aspect 59] 59. A crystalline form according to any one of embodiments 53 to 58, having an X-ray powder diffraction pattern comprising four or more of the following peaks at 2θ: 6.2°±0.2°; 10.4°±0.2°; 11.3°±0.2°; 11.9°±0.2°; 12.5°±0.2°; 13.8°±0.2°; 14.4°±0.2°; 15.6°±0.2°; 16.0°±0.2°; 16.7°±0.2°; 20.7°±0.2°; and 21.2°±0.2°. [Aspect 60] 60. The crystalline form of any one of embodiments 53 to 59, having an X-ray powder diffraction pattern substantially as shown in FIG. 14. [Aspect 61] The crystalline form of any one of embodiments 53 to 60, having a DSC thermogram comprising an endothermic peak having a maximum at about 179 °C. [Aspect 62] The crystalline form of any one of embodiments 53 to 61, having a differential scanning calorimetry thermogram (DSC) substantially as shown in FIG. 15. [Aspect 63] A salt which is 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide. [Aspect 64] 64. The salt according to embodiment 63, which is 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide in a 1:1 stoichiometric ratio to hydrobromic acid. [Aspect 65] 65. The salt according to embodiment 63 or 64, which is substantially isolated. [Aspect 66] 65. The salt according to embodiment 63 or 64, which is in a crystalline form. [Aspect 67] 67. The crystalline form according to embodiment 66, which is a solvated crystalline form. [Aspect 68] The crystalline form according to embodiment 67, which is a methanol solvate crystalline form. [Aspect 69] 70. The crystalline form of any one of embodiments 1 to 62, 67 and 68, which is substantially isolated. [Aspect 70] A composition comprising a crystalline form according to any one of aspects 1 to 62 and 67 to 69, or a salt according to any one of aspects 63 to 66. [Aspect 71] The composition according to embodiment 70, further comprising at least one pharma- ceutically acceptable carrier. [Aspect 72] A method for inhibiting the activity of PI3Kγ kinase, comprising contacting the kinase with a crystalline form according to any one of embodiments 1 to 62 and 67 to 69, or a salt according to any one of embodiments 63 to 66. [Aspect 73] The method of embodiment 72, wherein the crystalline form is a selective inhibitor of PI3K gamma over one or more of PI3K alpha, beta, and delta. [Aspect 74] A method of treating a disease or disorder associated with aberrant expression or activity of PI3Kγ kinase in a patient, the method comprising administering to the patient a therapeutically effective amount of a crystalline form according to any one of embodiments 1 to 62 and 67 to 69, or a salt according to any one of embodiments 63 to 66. [Aspect 75] The method of embodiment 74, wherein the disease or disorder is an autoimmune disease or disorder, cancer, a cardiovascular disease, or a neurodegenerative disease. [Aspect 76] The method of embodiment 74, wherein the disease or disorder is lung cancer, melanoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, colon cancer, endometrial cancer, bladder cancer, skin cancer, uterine cancer, renal cancer, gastric cancer, seminoma, teratocarcinoma, astrocytoma, neuroblastoma, glioma, or sarcoma. [Aspect 77] 77. The method of embodiment 76, wherein the sarcoma is Askin tumor, botryoid sarcoma, chondrosarcoma, Ewing sarcoma, malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans, desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), hemangiopericytoma, angiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, or undifferentiated pleomorphic sarcoma. [Aspect 78] 75. The method of embodiment 74, wherein the disease or disorder is acute myeloid leukemia, acute monocytic leukemia, small lymphocytic lymphoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma, T-cell acute lymphoblastic leukemia (T-ALL), cutaneous T-cell lymphoma, large granular lymphocytic leukemia, mature (peripheral) T-cell neoplasm (PTCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma. [Aspect 79] The method of embodiment 78, wherein said mature (peripheral) T-cell neoplasm (PTCL) is T-cell prolymphocytic leukemia, T-cell granular lymphocytic leukemia, aggressive NK-cell leukemia, mycosis fungoides / Sezary syndrome, anaplastic large cell lymphoma (T-cell type), enteropathic T-cell lymphoma, adult T-cell leukemia / lymphoma, or angioimmunoblastic T-cell lymphoma. [Aspect 80] The method of embodiment 78, wherein the anaplastic large cell lymphoma (ALCL) is systemic ALCL or primary cutaneous ALCL. [Aspect 81] The disease or disorder may be Burkitt's lymphoma, acute myeloblastic leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, hairy cell leukemia, mantle cell lymphoma, small lymphocytic lymphoma, follicular lymphoma, xeroderma pigmentosum, keratoacanthoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, Waldenstrom's macroglobulinemia, prolymphocytic leukemia, acute lymphoblastic leukemia, myelofibrosis, 75. The method of embodiment 74, wherein the tumor is selected from the group consisting of mucosa-associated lymphoid tissue (MALT) lymphoma, mediastinal (thymic) large B-cell lymphoma, lymphomatoid granulomatosis, splenic marginal zone lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, plasma cell leukemia, extramedullary plasmacytoma, smoldering myeloma (also known as asymptomatic myeloma), monoclonal gammopathy of undetermined significance (MGUS), or diffuse large B-cell lymphoma. [Aspect 82] The method of embodiment 81, wherein said non-Hodgkin's lymphoma (NHL) is relapsed NHL, refractory NHL, relapsed follicular NHL, indolent NHL (iNHL), or aggressive NHL (aNHL). [Aspect 83] 82. The method of embodiment 81, wherein said diffuse large B-cell lymphoma is activated B-cell-like (ABC) diffuse large B-cell lymphoma or germinal center B-cell (GCB) diffuse large B-cell lymphoma. [Aspect 84] The method of embodiment 81, wherein the Burkitt lymphoma is endemic Burkitt lymphoma, sporadic Burkitt lymphoma, or Burkitt-like lymphoma. [Aspect 85] 85. The method of embodiment 84, wherein the disease or disorder is rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, asthma, allergy, allergic rhinitis, pancreatitis, psoriasis, anaphylaxis, glomerulonephritis, inflammatory bowel disease, thrombosis, meningitis, encephalitis, diabetic retinopathy, benign prostatic hyperplasia, myasthenia gravis, Sjogren's syndrome, osteoarthritis, restenosis, or atherosclerosis. [Aspect 86] 85. The method of embodiment 84, wherein the disease or disorder is cardiac hypertrophy, cardiomyocyte dysfunction, acute coronary syndrome, chronic obstructive pulmonary disease (COPD), chronic bronchitis, elevated blood pressure, ischemia, ischemia-reperfusion, vasoconstriction, anemia, bacterial infection, viral infection, graft rejection, kidney disease, anaphylactic shock fibrosis, skeletal muscle atrophy, skeletal muscle hypertrophy, angiogenesis, sepsis, graft-versus-host disease, allogeneic or xenogeneic transplantation, glomerulosclerosis, progressive renal fibrosis, idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, vasculitis, systemic lupus erythematosus, lupus nephritis, pemphigus, or membranous nephropathy. [Aspect 87] The method of embodiment 86, wherein the idiopathic thrombocytopenic purpura (ITP) is recurrent ITP or refractory ITP. [Aspect 88] 87. The method of embodiment 86, wherein the vasculitis is Behcet's disease, Cogan's syndrome, giant cell arteritis, polymyalgia rheumatica (PMR), Takayasu's arteritis, Buerger's disease (thromboangiitis obliterans), central nervous system vasculitis, Kawasaki disease, polyarteritis nodosa, Churg-Strauss syndrome, mixed cryoglobulinemic vasculitis (essential or hepatitis C virus (HCV)-induced), Henoch-Schönlein purpura (HSP), hypersensitivity vasculitis, microscopic polyangiitis, Wegener's granulomatosis, or antineutrophil cytoplasmic antibody-associated (ANCA) systemic vasculitis (AASV). [Aspect 89] The method of embodiment 86, wherein the disease or disorder is Alzheimer's disease, central nervous system injury, or stroke. [Aspect 90] 1. A process for preparing a crystalline form of the compound 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, comprising dissolving the compound in a solvent to form a mixture and crystallizing the compound from the mixture. [Aspect 91] 91. The process of embodiment 90, wherein the solvent comprises isopropyl acetate. [Aspect 92] 92. The process of embodiment 91, wherein the solvent further comprises heptane. [Aspect 93] The process of any one of aspects 90 to 92, further comprising heating the mixture to a temperature of about 70° C. to about 90° C. [Aspect 94] 94. The process of embodiment 93, further comprising cooling the mixture to room temperature. [Aspect 95] 91. The process of embodiment 90, wherein the solvent comprises methanol. [Aspect 96] 91. The process of embodiment 90, further comprising heating the mixture to a temperature of about 50° C. to about 70° C. [Aspect 97] 97. The process of embodiment 96, further comprising cooling the mixture to room temperature. [Aspect 98] A crystalline form of the compound 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, prepared according to the process of any one of aspects 90 to 97. [Aspect 99] 99. The crystalline form according to embodiment 98, which is anhydrous and unsolvated. [Aspect 100] 100. The crystalline form according to embodiment 98 or 99, which is form IA. [Aspect 101] 100. The crystalline form according to embodiment 98 or 99, which is form IIA. [Aspect 102] 100. The crystalline form according to embodiment 98 or 99, which is form IIIA. [Aspect 103] 1. A process for preparing a crystalline form of the compound 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, comprising dissolving the compound in a solvent to form a mixture and crystallizing the compound from the mixture. [Aspect 104] The process of embodiment 103, further comprising heating the mixture to a temperature of about 70° C. to about 90° C. [Aspect 105] The process of embodiment 103, further comprising cooling the mixture to room temperature. [Aspect 106] 106. The process of any one of aspects 103 to 105, wherein the solvent comprises isopropyl acetate. [Aspect 107] The process of embodiment 106, wherein the solvent further comprises heptane. [Aspect 108] A crystalline form of the compound 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide prepared according to the process of any one of aspects 103 to 107. [Aspect 109] The crystalline form according to embodiment 108, which is anhydrous and unsolvated. [Aspect 110] 110. The crystalline form according to embodiment 108 or 109, which is form IB. [Aspect 111] 110. The crystalline form according to embodiment 108 or 109, which is form IIB. [Aspect 112] The compound 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-d 3 2. A process for preparing a crystalline form of 1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, comprising dissolving the compound in a solvent to form a mixture and crystallizing the compound from the mixture. [Aspect 113] 113. The process of embodiment 112, further comprising heating the mixture to a temperature of about 70° C. to about 90° C. [Aspect 114] 113. The process of embodiment 112, further comprising cooling the mixture to room temperature. [Aspect 115] 115. The process of any one of aspects 112 to 114, wherein the solvent comprises isopropyl acetate. [Aspect 116] The process of embodiment 115, wherein the solvent further comprises heptane. [Aspect 117] The compound 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d)) is prepared according to the process according to any one of aspects 112 to 116. 3 )-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide crystalline form. [Aspect 118] The crystalline form according to embodiment 117, which is anhydrous and unsolvated. [Aspect 119] 119. The crystalline form according to embodiment 117 or 118, which is form IC. [Aspect 120] 1. A process for preparing the hydrobromide salt of a compound, 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, comprising dissolving the compound in a solvent to form a mixture and adding hydrobromic acid to the mixture. [Aspect 121] 121. The process of embodiment 120, wherein the solvent comprises methanol. [Aspect 122] 122. The process of any one of embodiments 120 to 121, wherein the hydrobromic acid is added to the mixture as an aqueous solution of hydrobromic acid. [Aspect 123] 123. The process of any one of aspects 120 to 122, wherein an excess of hydrobromic acid based on 1 equivalent of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide is added to the mixture. [Aspect 124] 124. The process of any one of aspects 120 to 123, wherein about 1.1 to about 1.5 equivalents of hydrobromic acid based on 1 equivalent of the 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide is added to the mixture. [Aspect 125] 125. The process of any one of aspects 120 to 124, further comprising substantially isolating the 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide. [Aspect 126] The process of embodiment 125, wherein the 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide is isolated in a crystalline form. [Aspect 127] 127. The process of any one of embodiments 125 to 126, wherein the 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide is isolated as a methanol solvate crystalline form. [Aspect 128] 128. The hydrobromide salt of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide prepared according to the process of any one of aspects 120 to 127. [Aspect 129] The hydrobromide salt according to embodiment 128, which is crystalline. [Aspect 130] 130. The hydrobromide salt according to embodiment 129, which is a solvated crystalline form. [Aspect 131] 131. The hydrobromide salt according to embodiment 129 or 130, which is in a methanol solvate crystalline form.
Claims
1. A crystal of the compound 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, Form IA having an X-ray powder diffraction pattern including four or more of the following peaks in 2θ: 8.6°±0.2°; 9.5°±0.2°; 10.3°±0.2°; 13.0°±0.2°; 13.6°±0.2°; 14.2°±0.2°; 14.9°±0.2°; 17.3°±0.2°; 19.2°±0.2°; 20.6°±0.2°; 24.0°±0.2°; and 28.7°±0.2°; Form IIA having an X-ray powder diffraction pattern including four or more of the following peaks in angle 2θ: 9.1°±0.2°; 11.1°±0.2°; 12.6°±0.2°; 13.5°±0.2°; 18.0°±0.2°; 19.0°±0.2°; 20.5°±0.2°; and 21.9°±0.2°; and Form IIIA having an X-ray powder diffraction pattern including four or more of the following peaks in angle 2θ: 8.1°±0.2°; 10.6°±0.2°; 13.5°±0.2°; 14.2°±0.2°; 16.4°±0.2°; 17.1°±0.2°; 17.9°±0.2°; 20.3°±0.2°; and 24.1°±0.2°. The crystal is of a crystalline form selected from the group consisting of
2. The crystal of claim 1, which is anhydrous and unsolvated.
3. 3. The crystal of claim 1 or 2, wherein the crystalline form is Form IA.
4. The crystal of claim 3 having an X-ray powder diffraction pattern as shown in Figure 1.
5. A crystal described in claim 3 or 4, having a DSC thermogram including an endothermic peak having a maximum at 193°C.
6. 6. The crystal of any one of claims 3 to 5, having a differential scanning calorimetry thermogram (DSC) as shown in Figure 2.
7. 7. The crystal of any one of claims 3 to 6, having a thermogravimetric analysis (TGA) as shown in Figure 3.
8. 3. The crystal of claim 1 or 2, wherein the crystalline form is Form IIA.
9. 9. The crystal of claim 8 having an X-ray powder diffraction pattern as shown in FIG.
10. The crystal of claim 8 or 9, having a DSC thermogram including an endothermic peak having a maximum at 180°C.
11. 11. The crystal of any one of claims 8 to 10, having a differential scanning calorimetry thermogram (DSC) as shown in Figure 5.
12. 12. The crystal of any one of claims 8 to 11, having a thermogravimetric analysis (TGA) as shown in Figure 6.
13. 3. The crystal of claim 1 or 2, wherein the crystalline form is Form IIIA.
14. 14. The crystal of claim 13 having an X-ray powder diffraction pattern as shown in FIG.
15. A crystal described in claim 13 or 14, having a DSC thermogram including an endothermic peak having a maximum at 143°C.
16. 16. The crystal of any one of claims 13 to 15, having a differential scanning calorimetry thermogram (DSC) as shown in Figure 8.
17. 17. The crystal of any one of claims 13 to 16, having a thermogravimetric analysis (TGA) as shown in Figure 9.
18. A crystal of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide, the crystal having a stoichiometric ratio of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide to hydrobromic acid of 1:
1.
19. The crystal according to claim 18, which is a solvated crystal.
20. The crystal according to claim 19, which is a methanol solvate crystal.
21. A crystal described in any one of claims 1 to 20, which is isolated.
22. A composition comprising a crystal according to any one of claims 1 to 21.
23. 23. The composition of claim 22, further comprising at least one pharma- ceutically acceptable carrier.
24. A pharmaceutical for inhibiting the activity of PI3Kγ kinase, comprising a crystal according to any one of claims 1 to 21.
25. The pharmaceutical agent of claim 24, wherein the crystal is a selective inhibitor of PI3Kγ over one or more of PI3Kα, PI3Kβ, and PI3Kδ.
26. 22. A composition for treating a disease or disorder associated with abnormal expression or activity of PI3Kγ kinase in a patient, the composition comprising a crystal described in any one of claims 1 to 21.
27. 27. The composition of claim 26, wherein the disease or disorder is an autoimmune disease or disorder, cancer, a cardiovascular disease, or a neurodegenerative disease.
28. 27. The composition of claim 26, wherein the disease or disorder is lung cancer, melanoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, colon cancer, endometrial cancer, bladder cancer, skin cancer, uterine cancer, renal cancer, gastric cancer, seminoma, teratocarcinoma, astrocytoma, neuroblastoma, glioma, or sarcoma.
29. 29. The composition of claim 28, wherein the sarcoma is Askin tumor, botryoid sarcoma, chondrosarcoma, Ewing sarcoma, malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans, desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), hemangiopericytoma, angiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, or undifferentiated pleomorphic sarcoma.
30. 27. The composition of claim 26, wherein the disease or disorder is acute myeloid leukemia, acute monocytic leukemia, small lymphocytic lymphoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma, T-cell acute lymphoblastic leukemia (T-ALL), cutaneous T-cell lymphoma, large granular lymphocytic leukemia, mature (peripheral) T-cell neoplasm (PTCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma.
31. 31. The composition of claim 30, wherein the mature (peripheral) T cell neoplasm (PTCL) is T cell prolymphocytic leukemia, T cell granular lymphocytic leukemia, aggressive NK cell leukemia, mycosis fungoides / Sézary syndrome, anaplastic large cell lymphoma (T cell type), enteropathic T cell lymphoma, adult T cell leukemia / lymphoma, or angioimmunoblastic T cell lymphoma.
32. 31. The composition of claim 30, wherein the anaplastic large cell lymphoma (ALCL) is systemic ALCL or primary cutaneous ALCL.
33. The disease or disorder is selected from the group consisting of Burkitt's lymphoma, acute myeloblastic leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, hairy cell leukemia, mantle cell lymphoma, small lymphocytic lymphoma, follicular lymphoma, xeroderma pigmentosum, keratoacanthoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, Waldenstrom's macroglobulinemia, prolymphocytic leukemia, acute lymphoblastic leukemia, myelofibrosis, 27. The composition of claim 26, which is mucosa-associated lymphoid tissue (MALT) lymphoma, mediastinal (thymic) large B-cell lymphoma, lymphomatoid granulomatosis, splenic marginal zone lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, plasma cell leukemia, extramedullary plasmacytoma, smoldering myeloma (also known as asymptomatic myeloma), monoclonal gammopathy of undetermined significance (MGUS), or diffuse large B-cell lymphoma.
34. 34. The composition of claim 33, wherein the non-Hodgkin's lymphoma (NHL) is relapsed NHL, refractory NHL, relapsed follicular NHL, indolent NHL (iNHL), or aggressive NHL (aNHL).
35. 34. The composition of claim 33, wherein the diffuse large B-cell lymphoma is activated B-cell-like (ABC) diffuse large B-cell lymphoma or germinal center B-cell (GCB) diffuse large B-cell lymphoma.
36. 34. The composition of claim 33, wherein the Burkitt lymphoma is endemic Burkitt lymphoma, sporadic Burkitt lymphoma, or Burkitt-like lymphoma.
37. 27. The composition of claim 26, wherein the disease or disorder is rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, asthma, allergy, allergic rhinitis, pancreatitis, psoriasis, anaphylaxis, glomerulonephritis, inflammatory bowel disease, thrombosis, meningitis, encephalitis, diabetic retinopathy, benign prostatic hyperplasia, myasthenia gravis, Sjogren's syndrome, osteoarthritis, restenosis, or atherosclerosis.
38. 27. The composition of claim 26, wherein the disease or disorder is cardiac hypertrophy, cardiomyocyte dysfunction, acute coronary syndrome, chronic obstructive pulmonary disease (COPD), chronic bronchitis, elevated blood pressure, ischemia, ischemia-reperfusion, vasoconstriction, anemia, bacterial infection, viral infection, graft rejection, kidney disease, anaphylactic shock fibrosis, skeletal muscle atrophy, skeletal muscle hypertrophy, angiogenesis, sepsis, graft-versus-host disease, allogeneic or xenogeneic transplantation, glomerulosclerosis, progressive renal fibrosis, idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, vasculitis, systemic lupus erythematosus, lupus nephritis, pemphigus, or membranous nephropathy.
39. 39. The composition of claim 38, wherein the idiopathic thrombocytopenic purpura (ITP) is recurrent ITP or refractory ITP.
40. 39. The composition of claim 38, wherein the vasculitis is Behcet's disease, Cogan's syndrome, giant cell arteritis, polymyalgia rheumatica (PMR), Takayasu's arteritis, Buerger's disease (thromboangiitis obliterans), central nervous system vasculitis, Kawasaki disease, polyarteritis nodosa, Churg-Strauss syndrome, mixed cryoglobulinemic vasculitis (essential or hepatitis C virus (HCV)-induced), Henoch-Schonlein purpura (HSP), hypersensitivity vasculitis, microscopic polyangiitis, Wegener's granulomatosis, or antineutrophil cytoplasmic antibody-associated (ANCA) systemic vasculitis (AASV).
41. 27. The composition of claim 26, wherein the disease or disorder is Alzheimer's disease, central nervous system injury, or stroke.
42. 1. A process for preparing crystals of the compound 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, comprising dissolving the compound in a solvent to form a mixture and crystallizing the compound from the mixture.
43. 43. The process of claim 42, wherein the solvent comprises isopropyl acetate.
44. 44. The process of claim 43, wherein the solvent further comprises heptane.
45. 45. The process of any one of claims 42 to 44, further comprising heating the mixture to a temperature of from 70°C to 90°C.
46. 46. The process of claim 45, further comprising cooling the mixture to room temperature.
47. 43. The process of claim 42, wherein the solvent comprises methanol.
48. 43. The process of claim 42, further comprising heating the mixture to a temperature of from 50°C to 70°C.
49. 49. The process of claim 48, further comprising cooling the mixture to room temperature.
50. 1. A process for preparing the hydrobromide salt of a compound, 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, comprising dissolving the compound in a solvent to form a mixture and adding hydrobromic acid to the mixture.
51. 51. The process of claim 50, wherein the solvent comprises methanol.
52. 52. The process of claim 50 or 51, wherein the hydrobromic acid is added to the mixture as an aqueous solution of hydrobromic acid.
53. 53. The process of any one of claims 50 to 52, wherein an excess of hydrobromic acid based on one equivalent of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide is added to the mixture.
54. 54. The process of any one of claims 50 to 53, wherein 1.1 to 1.5 equivalents of hydrobromic acid based on 1 equivalent of the 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide are added to the mixture.
55. 55. The process of any one of claims 50 to 54, further comprising isolating the 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide.
56. 56. The process of claim 55, wherein the 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide is isolated as a crystal.
57. 57. The process of claim 55 or 56, wherein the 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide hydrobromide is isolated as a crystalline methanol solvate.
Citation Information
Patent Citations
JPP7244504B
Heterocyclic compounds as PI3k-γ inhibitors
WO2017223414A1
